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Success is not measured by what a man accomplishes, but by the opposition he has 
encountered and the courage with which he has maintained the struggle against 
overwhelming odds.  
Charles Lindbergh 
     
  
  
  
ABSTRACT 
In Sweden, more than 6000 new patients were diagnosed with colorectal cancer in 2015 of 
which over 4000 patients had colon cancer and 1800 died from the disease. It is the second 
most common cancer after breast- and prostate cancer. In the last decade, significant 
improvement in the treatment of both rectal and colon cancer have been achieved.  
Diagnostic imaging, using CT, MRI and PET/CT, has become essential in the preoperative 
work-up. New neoadjuvant treatment strategies are under study in colon cancer. In the 
selection of patients for these treatments, pre- and post-treatment imaging has also become of 
interest. The overall aim of this thesis is to evaluate cross sectional imaging modalities for 
detection of colonic polyps and staging of patients with colon cancer using CT and MRI. 
The aim of paper 1 was to investigate the impact of radiation dose and spatial resolution in 
detecting colonic polyps in a phantom study simulating computed tomographic colonography 
(CTC). By using different scanning protocols with different slice -thickness, pitch and tube 
current we showed that the dose level could be substantially reduced by lowering the tube 
current without compromising the detection rate for polyps larger than 5 mm.  
The aim of paper 2 was to evaluate if high resolution MRI of colon cancer contributed to the 
standard staging procedure with CT with respect to assessment of local tumour extent, nodal 
staging and extramural venous invasion (EMVI). An advantage of MRI over CT due to its 
soft tissue discrimination to identify prognostic factors such as tumour stage and extramural 
venous invasion was found. The result of nodal staging for both modalities were equally 
moderate. 
The aim of paper 3 was to evaluate commonly used imaging CT criteria for lymph node 
metastases in predicting stage III disease. Of the different imaging criteria, morphological 
features performed best specifically internal heterogeneity and irregular outer border. None of 
the size criteria were predictive.  
The aim of paper 4 was to validate morphological CT criteria from paper 3 in a prospectively 
collected patient cohort using two observers. By using the criteria internal heterogeneity and a 
combination including irregular outer border, a moderate sensitivity and high specificity was 
achieved predicting stage III disease.  
CT and high resolution MRI can be used to classify colonic tumours into not locally 
advanced or locally advanced. The prediction of lymph node metastases with the most 
commonly used image modalities is however unsettled and challenged. In the setting of 
selecting patients to neoadjuvant chemotherapy, the ongoing trials so far have used inclusion 
criteria based on tumour T-stage only (T3cd-T4 as locally advanced). Patients with lower 
tumour T-stage but still have other adverse prognostic feature such as regional metastases 
will therefore potentially be undertreated and patients with no metastases will potentially be 
overtreated. Search for other prognostic factors identified on cross sectional imaging has to be 
performed. 
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1 BACKGROUND 
1.1 EPIDEMIOLOGY 
Colorectal cancer is one of the most common cancer in the world with 1.3 million new cases 
in 2012 (1). According to Sweden, 6759 new patients were diagnosed with colorectal cancer 
in 2015 of which 4490 patients with colon cancer and 1869 patients died from the disease (2). 
The incidence is increasing with age and 75% of the patients are over 65 years and only 5% 
are under 50 years of age. The mortality of colon cancer is slowly decreasing (3) (Figure 1). 
 
Figure 1. According to age-standardized of incidence and mortality from colon cancer for a) men and b) women 
per 100 000 individuals in Sweden 1970-2015 (3). 
 
The survival decreases with increasing stage. Of all poor prognostic factors, T-stage is the 
most important and recent publications show as high as >90% in relative 5-year survival rate 
in early stage colon cancer (stage I). There are differences and overlap in the 5-year survival 
between the sub stages of stage II (stage IIA 87%, IIB 63%) and stage III (stage IIIA 89%, 
IIIB 69%, stage IIIC 53%) (4). Metastatic disease (stage IV) have poor prognosis and as low 
as <20% in 5-year survival has been reported. 
 
1.2 AETIOLOGY OF COLON CANCER 
The development of cancer starts in a single cell and through several steps of changing it 
eventually turns to a cancer cell with capability to invade nearby tissues and metastasize. 
Those changes are based on the person’s genetic and epigenetic factors and control the cells 
signalling system, cell function and angiogenesis. 
Colorectal cancer results mostly from the progressive accumulation of genetic and epigenetic 
alterations which transforms the normal colonic epithelium to colon adenocarcinoma (5). 
Other less common cancer forms in colon are carcinoid, leiomyosarcoma and lymphoma. 
  8 
1.2.1 Cancer genetics and epigenetics 
The general description of cancer development from a single cell is genetic and epigenetic 
modifications that will alter the signal transmission between cells, cell cycle function, 
genome stability and induce angiogenesis causing uncontrolled cell growth and the ability to 
disrespect natural borders and metastasize. Adenocarcinomas develops from a normal 
epithelial gland cell into a cancer cell in several steps and the most well-known pathogenesis 
is the chromosomal instability pathway also called adenoma - carcinoma sequence (6, 7). 
Genetic events along the adenoma-carcinoma sequence lead to the development of sequential 
transformation from normal to dysplastic epithelium and finally to colorectal cancer by 
specific genetic changes. Accumulated both genetic and epigenetic alterations of the cellular 
genome transforms lead to changes from normal glandular epithelium into adenocarcinoma. 
The genetic mechanisms for cancer development are mainly caused by alterations in 
oncogenes, tumour suppressor genes and DNA repair genes (8). 
The most common genetic cause of CRC development is mutations in the oncogene. KRAS 
mutations leading to cell growth, proliferation and metastasis (9, 10). 
Mutation in tumour suppressor genes causes effects on cell regulation, growth factors and 
lack of control of apoptosis. The adenoma polyposis coli (APC) gene are mutated in up to 
70% of all sporadic adenocarcinomas in colon cancer (11, 12). Other tumour suppressor 
genes in this family are DCC and TP53 (6, 13). 
DNA repair genes (mismatch repair genes, MMR genes) participates in the maintaining the 
stability of the genome during the DNA replication. There are several mismatch genes known 
(hMLH1, hMSH2, hPMS2 etc.) and one event of mutation causes non-coding sequences of 
DNA accumulates called microsatellite instability (MSI) or replication errors (14). If 
mutations of repair genes occur it will accelerate mutations in oncogenes and tumour 
suppressor genes. MSI is frequently observed in LS patients and up to 15% of sporadic 
colorectal cancer (15). 
Carcinoembryonic antigen (CEA) is an important standard biomarker in CRC. CEA is a 
family of glycoproteins predominately on the cell membrane and is overexpressed in CRC 
and is thought to be involved in the ability to metastasize (16). Because of its poor sensitivity 
and specificity as a screening tool or in diagnosis in early stage CRC the biomarker is used 
for predicting prognosis, monitoring recurrence and treatment response (17). 
1.2.2 Heredity - Family history - Predisposition  
Age is the most important risk factor for colorectal cancer and the incidence is increasing 
over the age of 50 (3). Based on genetic background most of the acquired colorectal cancer 
(>80%) are sporadic cancers (18). There are inherited forms of polyposis syndromes such as 
familial adenomatous polyposis (FAP), Lynch syndrome (LS), (former called hereditary non 
polyposis coli (HNPCC)) with increased risk of developing CRC. 
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FAP is a rare syndrome and accounts for ~1% of CRC, where the patients in early 
adolescence starts to develop small polyps which could be hundreds to thousands of 
adenomatous polyps in the colon and rectum later in life. Some of the benign adenomas will 
grow into adenocarcinomas. Annual colonoscopy is recommended from the age of 12 for 
removal of polyps until total colectomy is performed (19). Nearly 95% of the patients have 
mutations in the tumour suppressor gene adenomatous polyposis coli (APC) (20). There are 
variants of FAP depending of mutated genes such as Peutz-Jeghers disease and MUTYH-
associated polyposis (MAP). 
LS accounts for up to 5 % of CRC and the most common form of hereditary CRC (14). These 
patients have a mutation in one of the DNA mismatch repair (MMR) genes (MLH-1, MSH-2, 
MSH-6 and PMS-2). Compared to FAP, patients with LS do not develop the same amount of 
polyps but the polyps can develop into cancer in 1-2 years. Colonoscopy, at least biannually, 
is recommended in this group of patients. Patients with LS also have an increased risk of 
developing cancer in other organs such as endometrium, ovary, stomach, hepatobiliary tract 
upper urinary tract, skin and the brain. 
Environmental and life style factors play a role in the incidence of colon cancer that may 
induce genetic end epigenetic changes in the cells. Dietary factors as red meat, low intake of 
vegetables, fruit and fibers have been proposed having an effect on developing colorectal 
cancer. Obesity and obesity related insulin resistance and associated hyper-insulinemia are 
assumed to be associated with colon cancer pathogenesis (21, 22). High alcohol intake and 
smoking also contributes in developing cancer (23). By altering dietary factors as red meat 
reduction, increase fruit and vegetables intake and lifestyle factors as weight control, increase 
exercise and reduced alcohol consumption, a reduction of 15-30% of developing colorectal 
cancer have been estimated (24). Dietary micronutrients such as vitamin A, C, E, beta-
carotene and selenium have anti-oxidant or anti-inflammatory effects and are considered to 
have anti-carcinogenic effect (25, 26). The use of aspirin and related non-steroidal anti-
inflammatory drugs has in epidemiological studies and clinical trials have indicated an effect 
against colorectal cancer but the mechanisms are not fully understood (27-29). 
Inflammatory bowel disease, ulcerative colitis, is associated with a cumulative risk of colon 
cancer and is increasing over the years with the disease (30). 
1.3 EMBRYOLOGY AND ANATOMY 
Colon can be divided in subparts; the caecum, ascending-, transverse-, descending- and 
sigmoid colon. The rectum and anal canal are the distal parts of gastro intestinal tract. The 
anatomical definition of the rectum is at the level of the third sacral segment, where there is 
no posterior peritoneum, and the surgical definition is at the sacral promontory. The rectum is 
usually defined as the distal part 12-15 cm from anal verge. 
The gastro intestinal tract originates from a primitive tube forming the foregut, midgut and 
hindgut. The foregut is forming the GI tract to the end of the duodenal ampulla. The midgut is 
extending from duodenal ampulla to the distal part of the transverse colon and is supplied by 
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the ileocolic artery (ICA) and the middle colic artery (MCA), both originating from superior 
mesenteric artery (SMA). The distal third of the transverse colon, descending colon and 
rectum develops from the hindgut and are supplied by the inferior mesenteric artery (IMA). 
Between braches of these vessels, the colon segments are supplied by marginal arcades. In 
the mesentery, in which the bowel is attached, runs the supplying arteries, veins, nerves, 
lymphatic drainage, local- and regional lymph nodes (Figure 2). 
                                         
Figure 2. Schematic anatomical figure of the vessel supply of the colon. Note: SMA=superior mesenteric artery, 
IMA=inferior mesenteric artery, ICA=ileocolic artery, MCA=medial colic artery. 
The posterior surface of ascending and descending colon are fused and fixed to the 
retroperitoneum and the anterior and lateral aspects are covered with serosa, and are to be 
regarded as intraperitoneal structures. The transverse colon and the sigmoid colon are almost 
covered with serosa and are regarded as intraperitoneal (Figure 3). Rectum is covered with 
surrounding fat, mesorectum, and below the peritoneal reflection fixed within this 
mesorectum.  
             
a)                                                                              b)                                                                                                                                                    
Figure 3. Schematic anatomical figure of peritoneal coverage (red line) and the site of sharp dissection (blue line) 
in different parts of the colon where a) represents ascending and descending colon and b) represents the 
transverse colon and the sigmoid colon. Modified schematic figure from SCRCR (31). 
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The large bowel wall consists of several layers. The epithelium or mucosa, towards the lumen 
of the bowel, harbours the glands. The muscularis mucuosae, the submucosa, the muscularis 
propria regulates the autonomous bowel movements. The outer layer, serosa, is the fascia 
towards the peritoneal cavity (Figure 4). 
      
Figure 4. Illustration of colonic wall and different stages of colon cancer (stage 0-IV). For the National Cancer 
Institute © 2005 Terese Winslow LLC, U.S. Govt. has certain rights. 
1.4 HISTOPATHOLOGY 
1.4.1 General 
The grading and staging system of CRC is based according to WHO Classification of 
tumours of the digestive system 2010 and the 7th edition of UICC/TNM Classification of 
Malignant tumours (32, 33). The adenocarcinomas infiltrates into and eventually outside the 
bowel wall and tend to bulge into the bowel lumen (Figure 4). Microscopically, the tumour 
cells are atypical glandular cells and based on the glandular appearance in the microscope the 
tumour cells are divided into low or high differentiated. Other subtypes of CRC are mucinous 
adenocarcinomas. These are composed of large pools of extracellular mucin (>50%). Signet-
ring carcinomas are tumours with intracytoplasmic mucin. Both these subtypes have poorer 
outcome with higher rate of recurrence and decreased survival (34-36). Other tumour entities 
in the colon are carcinoids, lymphomas or leiomyosarcomas. The projects included in this 
thesis will focus on adenocarcinomas. 
After a biopsy of the polyp/lesion or surgical resection, biopsies and specimen are carefully 
taken care of by a pathologist performing gross sectional examination either on a fresh or 
paraffin embedded specimen. This is followed by a microscopic examination after staining 
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using haematoxylin and eosin to visually separate the cell nuclei from other tissue structures 
for further morphological assessment. 
1.4.2 Staging TNM 
Colorectal cancer is classified according to the tumour invasion depth of the bowel wall (T-
stage), tumour invasion in lymph nodes (N-stage) and presence of distant metastases (M-
stage) in the TNM classification system of malignant tumours (TNM) (33) (Table 1). For 
therapeutically guidance and for prognostic information the TNM stages are combined into 
an overall stage definition; Union International Contre le Cancer (UICC) (Table 2). 
Tumour stage 
The size of the tumour has limited prognostic significance (37). The tumour arises from the 
glands in the epithelium/mucosa and can grow through the layers of the bowel wall. If the 
tumour is confined within the bowel wall it is classified as T2.  If the tumour is growing 
outside the layer of muscularis propria and out in the surrounding mesenteric fat it is defined 
as T3. Depending on the depth of extra mural tumour extent, T3 tumour stage can be further 
subdivided in T3a (1mm tumour extent outside the MP), T3b (<5mm), T3c (5-15mm) and 
T3d (>15mm). If the tumour is growing directly into the peritoneal cavity through the serosa 
layer or to an adjacent organ or structure the tumour is classified as T4. 
Nodal stage 
The lymphatic drainage and lymph nodes runs along the vessels (arteries) within the 
mesentery. The lymph nodes adjacent to the tumour are called local lymph nodes and the 
lymph nodes more central in the mesentery are called regional lymph nodes. Lymph nodes 
around the aorta are categorised as distant lymph nodes and is not part of N-stage 
classification. Lymph nodes maybe be gradually infiltrated by tumour and normal lymph 
node cells will be replaced by tumour cells. If further invasion the tumour cells occur tumour 
will grow outside the lymph node, so called periglandular growth. 
Metastases 
The mechanisms for tumour spread are vascular (haematogenous), lymphogenic, perineural 
or direct spread into the peritoneal cavity and other organs (38, 39). In haematogenous 
spread, tumour cells spread through the blood stream to distant organs. The lymphatic spread 
originates from local lymph nodes and follow the lymph vessels to regional and distant lymph 
nodes and then enter the systemic circulation and thereafter distant organ metastases (39). 
Distant metastases are mainly located in the liver, lungs and central lymph nodes around the 
aorta and in the peritoneal cavity (peritoneum), but other locations could also be present such 
as the brain and bone (40). Presence of liver metastases has been reported as high as 15-
23%in patients with CRC at the time of diagnosis and up to 50 - 70% will develop liver 
metastases at follow up (41, 42). The second most common metastatic organ is the lungs but 
pulmonary metastases are more common in rectal cancer than in colon cancer. This is thought 
to be due to the venous circulation and the rectal veins are connected with the systemic 
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circulation whilst the veins colon drains via the portal veins to the liver (43). The main 
importance of this is that rectal cancer may spread into the lungs before metastasizing to the 
liver. Presence of small (<10 mm) nodules in the lungs on CT is sometimes difficult to 
interpret regarding their significance. These intermediate nodules are therefore re-examined  
in follow up program (31). In absence of liver metastases, there is a small risk of having lung 
metastases alone (44, 45). In absence of metastases in the liver or the lungs, other organ sites 
are uncommon (46).  
 
T-Tumour stage  T1 Tumour growing in the inner surface, mucosa/submucosa 
  T2 Tumour growing into the muscularis propria layer 
  T3 Tumour growing outside the wall - T3a, T3b, T3c, T3d 
  T4 T4a - Peritoneal spread    T4b - Adjacent organ  
     or structure 
N-Nodal stage  N0 No lymph node metastases 
  N1 1-3 lymph node metastases - N1a, N1b, N1c (td) 
  N2 4+ lymph node metastases - N2a, N2b 
M-Metastases  M0 No metastases 
  M1 Distant metastases - M1a, M1b 
Table 1. TNM classification 7th edition. 
 
 
AJCC/UICC staging system T-stage N-stage M-stage 
Stage 0 Tis N0 M0 
Stage I T1, T2 N0 M0 
Stage II T3, T4 N0 M0 
Stage IIA T3 N0 M0 
Stage IIB T4a N0 M0 
Stage IIC T4b N0 M0 
Stage III Any T N1, N2 M0 
Stage IIIA T1, T2 N1 M0 
 T1 N2a M0 
Stage IIIB T3, T4a N1 M0 
 T2, T3 N2a M0 
 T1, T2 N2b M0 
Stage IIIC T4a N2a M0 
 T3, T4a N2b M0 
 T4b N1, N2 M0 
Stage IV Any T Any N M1 
Stage IVA Any T Any N M1a 
Stage IVB Any T Any N M1b 
 
Table 2. Classification for colorectal cancer according to AJCC/UICC staging system. 
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Residual Tumour Classification and circumferential resections margins. 
The residual tumour classification reflects tumour status after surgery and demonstrates 
absence or presence of tumour at the resection margin (33) (Table 3). Tumour near or 
reaching the circumferential resection margin is referred as circumferential resection margin 
(CRM) positive. When performing surgery it is important to know if the standard surgical 
procedure has to be modified to achieve R0 resection. If the surgical margin is involved or if 
the distance is short (<1mm) the risk of recurrent tumour is high and the prognosis worse than 
if there is a R0 resection or involvement of the CRM (47, 48). 
 
 
R0 No residual tumour, minimal distance between tumour and resection margin >1 mm 
R1 Microscopic residual tumour 
R2 Macroscopic residual tumour  
Table 3. Residual Tumour Classification. 
 
Histopathological prognostic factors 
Poor prognostic factors beyond high stage are factors that worsen the prognosis and outcome 
for the patient. Examples of those recorded in the pathologists report are; tumour invasion in 
veins (EMVI), lymph vessel or perineural spaces. If a tumour extent beyond the bowel wall 
the tumour can infiltrate the nearby small veins (EMVI) and lymph vessels. Regarding 
venous invasion additional immunohistochemical tests with the endothelial marker CD31 and 
CD34 and for lymphatic marker D2-40 can be used. Extra nodal extension growth (ENE) is 
associated with poorer outcome as overall survival and risk of recurrence (49). 
Biomarkers 
Many biomarkers are described in literature but not in standard use. To get additional 
information from the tissue, biomarkers as microsatellite instability (MSI) and chromosomal 
instability (CIN) can be tested, potentially useful for deciding further treatment (50). For 
patients suitable for adjuvant treatment biomarkers for mutation of KRAS and BRAF can be 
used (51). 
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1.5  COLON CANCER DIAGNOSIS 
1.5.1 Clinical and laboratory 
Since 2016 new care flows for management of cancer have been introduced in Sweden. 
These are called SVF (standardiserat vårdförlopp) or standardized care flows. Patients with 
symptoms indicating colorectal cancer are categorised into degrees of suspicion of having a 
colorectal tumour. Examples of symptoms are altered bowel habits, blood in stool, anaemia 
and weight loss. The new management aims at shortening the investigation time for 
colonoscopy, histopathology and imaging to diagnose and start treatment within certain time 
limits (31). 
Patients with suspected colorectal disease are first clinically examined including rectal 
palpation and procto-rectoscopy. Laboratory test as faecal occult blood test (FOBT) or faecal 
immunochemical test (FIT) and serum carcinoembryonic antigen (CEA) are performed (31). 
In Stockholm-Gotland a screening program is ongoing (age 60-69) since 2008 using FOBT 
biannually. The Screening for Swedish Colons (SCREESCO) study started in 2014 to 
compare screening strategies such as colonoscopy or FIT. Screening for colorectal cancer has 
been found to be cost effective compared with no screening with favour for repeated 
colonoscopy (52). 
1.5.2 Optical Colonoscopy (OS) 
Flexible sigmoidoscopy or OS is the first line examination after clinical examination. The 
examination is performed after a fully cleansed bowel. If suspicion of a polyp or a tumour, 
multiple biopsies are taken and analysed by a GI pathologist. A complete OS of the whole 
colon requires caecal intubation and the procedure is highly dependent on the individual 
expertise of the endoscopist (53). As a quality level for a successful OS >90% is 
recommended (54). When the whole colon can not be visualised by OS the examination is 
reported as incomplete. The reported rate of incomplete OS is approximately 10-15% (55, 
56). 
1.5.3 Computed Tomography (CT) 
A computed tomography (CT) scanner consists of a X-ray generator and a detector, placed in 
diametrically opposite side, that rotates around an object (i.e. the body of a patient) and 
measures the density of tissues. The technique was rewarded the Nobel Prize in 1979 (57). 
The first scanners in the late 1970´s consisted of one X-ray source and one opposite detector. 
After one rotation of the x-ray source and detector the patient moved and the next rotation 
was initiated. Only axial images were obtained with this technique. Later, developments 
resulted in faster acquisitions, continuously moving table and newer detector configurations 
than single-slice CT allowing volumetric examinations to create images in various planes. 
Today the modern CT scanner has developed to have sub millimetre multidetector 
configuration called multidetector-CT (MDCT) and offers fast scanning time, multiplanare 
image reconstructions in 2D and 3D and offers different optimization techniques for radiation 
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dose reduction. A further development is Dual Energy Computed Tomography (DECT). It is 
a technique that have been available since the late 2000s. The technique combines two 
different spectra of energy based on their tube voltage (often 80 and 140 kV) to separate and 
characterize the body tissue. DECT has been used for subtraction of high density material 
such as bones, osteosynthesis material and kidney stones but could also be used for iodine 
quantification in tumour volume assessment. Some studies have also shown the potential to 
reduce radiation dose using DECT compared to commonly used (single energy) CT (SECT) 
(58). 
In colorectal cancer, a full examination of the thorax and abdomen is performed to stage the 
tumour and presence of distant metastases. The examination is performed with intra venous 
contrast (ivc) material which is administered via a peripheral venous catheter. The CT scan 
protocol is generally performed using a multi detector CT with 64 slices or more detectors 
that generate sections which are typically in order of 0.625 mm thick. The original sections 
can be reconstructed to thicker image slices, normally 2-5 mm, in three orthogonal planes; 
axial, sagittal and coronal. The scans are normally acquired in the portal-venous phase when 
the contrast medium has reached the solid vascularized organs of the body. When tumour 
staging is addressed, scanning is typically performed in three different phases; native (before 
ivc), arterial phase and portal-venous phase mainly in order to assess the liver. If suspicion of 
focal lever lesions (not benign) dedicated ultrasound (including intravenous contrast agent – 
micro bubbles) or MRI examination of the liver is performed. 
Computed Tomographic Colonography (CTC) 
CTC is an alternative to OS and was mainly introduced when CT went from single slice to 
multi slice thus enabling thin slices and more volumetric applications. The technique was 
described in the 90´s (59, 60). CTC has out concurred the former colon examination method 
of double-contrast barium enema (DCBE) (55). In CTC, not only cross sectional imaging of 
the bowel and adjacent organs can be performed but also allowing assessment of the bowel 
wall by distending the bowel with air or carbon dioxide. The examination is evaluated using 
2D and 3D-reconstructions (fly-through) in a manner that makes some of the visual 
interpretation similar to OS. Even though OS is the golden standard for polyp detection, the 
false negative rate using this technique has been reported as high as over 25 % (61-63). For 
detecting CRC, CTC is comparable to OS (64, 65). In order to locate the tumour site CTC 
performed better than OS especially in the left colon (66). In cases of incomplete preoperative 
OS when there is no possibility to evaluate the colon proximal to the tumour, CTC can 
therefore be useful to assess the whole colon. This examination is also useful when the 
patient cannot tolerate OS. CTC is less invasive than OS and the detection accuracy in both 
high-risk population and low prevalence group are similar. There are guidelines regarding 
clinical indications for CTC from European Society of Gastrointestinal Endoscopy (ESGE) 
and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) and also a 
consensus statement how to perform, interpret and report CTC (55, 67). 
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When performing CTC, the patient is examined in both prone and supine position after bowel 
cleansing and gas (CO2 or air) administered via a catheter in the rectum to distend the colon. 
CTC can also be performed without intra venous contrast and with lower radiation dose 
compared with the dose used for tumour staging. The low dose technique is used when 
detection of polyps is the primary issue, such as for screening purposes and as an alternative 
to OS. The radiation dose depends on the tube voltage, tube current setting, the pitch factor 
and the collimated beam size. To adapt CT to a low-dose configuration there will always be a 
trade-off between the radiation dose and spatial resolution. A typical low-dose protocol 
consists of high tube voltage and low tube current and high pitch. This will create images 
suitable for detection of intra luminal findings in the colon but no assessment of bowel wall 
or parenchymal findings. There are different approaches to colon cancer screening in the 
world. In Sweden there is an ongoing study and screening program (SCREESCO) for patients 
between 59-62 years of age comparing colonoscopy and a modified F-Hb test so called FIT. 
CTC has a high sensitivity for polyps/tumours  ≥6mm (68). 
    
1.5.4 Magnetic Resonance Imaging (MRI) 
Nuclear magnetic resonance (NMR) technique has originated from the early 1930-40. The 
technique has developed massively during the following years and many research groups and 
researchers have contributed to its success which have been rewarded with the Nobel prize in 
2003 (69). MRI uses the electromagnetic activity of atomic nuclei (the protons). The protons 
are positively charged and have spins around its own axis. In MRI, the technique is based on 
odd numbered nuclei and the spins of the protons and neutrons do not cancel each other out 
and induces a magnetic field. In clinical MRI hydrogen protons is used because of the vast 
amount of in the body in forms of water and fat. When the hydrogen protons are into a MRI 
scanner, which consists of a great outer magnetic field (B0), the hydrogen protons spin 
interacts with the external field causes the nuclei to wobble or precess. Some protons are 
parallel to the magnetic axis and some are in the opposite direction. The sum of all magnetic 
moments is a net magnetization vector (M). 
To generate images in MRI, radio frequency pulses (gradients) in the magnetic fields are 
generated. These gradients will form differences in the magnetic field in defined directions in 
the body. When the gradients are turned on the M-vector will flip and when the gradients are 
turned off the protons will return to the relax state and emit radio frequency waves and an 
antenna coil will receive the signal to be used for further image creation. There are two main 
types of pulse sequences to generate images; spin-echo (SE) and gradient echo (GRE) 
sequences. The SE sequences are designed to reduce the artefacts due to in homogeneities in 
the magnetic field and take a relatively longer time to accomplish than GRE sequences. The 
GRE sequences on the other hand are more sensitive for those artefacts but are much faster. 
There are numerous variants of these pulse sequences. 
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By varying the different parameters of the pulse sequences, image contrast can be produced 
between different tissues depending of the relaxation characteristics in the body. 
To create contrast in the morphological images, the different tissues T1 and T2 effects are 
used. The T1 effect represent the time after a RF pulse to restore magnetization in the 
longitudinal plane and T2 effect represent the dephasing of protons after a RF pulse in the 
transverse plane. 
In T1w imaging the goal is to present the difference in T1-relaxation between different 
tissues depending on their proton/fat content. Fat relax relatively fast and water relatively 
slow. In these images fat will appear with a high image signal intensity and water with a low 
image signal intensity. 
T2w imaging is mostly based on SE sequences (usually turbo or fast SE, TSE or FSE). In T2 
imaging water will appear with high and fat with moderate signal intensity. Depending on the 
degree of T2-weighted imaging used, images can either display different tissues or water only 
content as in magnetic resonance cholangiopancreaticography (MRCP). 
Modern clinical MRI scanners typically use a static magnetic field of 1.5 or 3.0 Tesla (T). For 
some purposes even higher field strengths are used as high as 7.0 T or more, in particular in 
the research setting. To receive the signal (radio waves) from the body parts, coils (or 
antennas) are used. There are different types of coils, in build coil in the scanner or surface 
body coils, to be attached on the body part examined. Several surface coils can be connected 
together to cover a larger examination area – so called phased array coils. 
In rectal cancer, MRI has for more than a decade been the modality of choice for local 
staging of the tumour. Dedicated protocols based on T2w imaging in three orthogonal planes; 
axial, sagittal and coronal, and an additional plane perpendicular to the tumour to assess the 
extension and tumour penetrating the bowel wall can be performed. For colon cancer there is 
a broad range of anatomy to consider when performing MRI. MRI of the colon is generally 
more time consuming and sensitive for motion artefacts (breathing or bowel movements) 
depending on which part of the colon. To reduce motions artefacts breath-hold sequences are 
usually preferable. To reduce bowel motion artefacts spasmolytic drugs are also 
recommended. 
Applications for MRI examinations of the colon  
MR colonography (MRC) is a technique to detect colonic lesions with MRI. MRC requires 
the same bowel preparations as CTC and oral contrast tagging material is preferable (70). 
Even if prolonging the scanning time, dual positioning is the most recommended use (71). As 
in CTC, an antispasmodic drug is used to minimize bowel peristalsis. Intravenous contrast 
agent could also be used to differentiate between polyps and residual stool, fluid and air. To 
cover the entire colon it is preferable to use surface coils in conjunction with the body coil. 
MRC can be performed in two ways; with bright-lumen or dark-lumen technique. In 
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detecting colonic lesions MRC have similar reported sensitivities and specificities compared 
to CTC but the major drawback is the low detection rate for polyps <5mm (72, 73). 
The term bright-lumen MRC is referred to installation of water and diluted gadolinium (Gd) 
chelate solution in the bowel. Pockets of air will be black and interfere with the interpretation 
of intra luminal lesions. The dual positioning is mandatory with this technique. 
The term dark-lumen MRC is referred to the bowel lumen is dark by insufflation of air or 
carbon dioxide for the distention of the colon as in CTC and this technique is more used in 
the clinical practice compared to bright lumen MRI (74). Some interference of residual water 
tend to occur when using this technique. 
Both bright and dark lumen colonic MRI have not gained clinical acceptance as an alternative 
to OS such as CTC. Reasons for this are the technical challenges and cost. 
High resolution MRI 
When performing tumour staging it is important to have adequate pulse sequences and 
receiver coils (usually phased array surface coils) with high spatial resolution and acceptable 
signal to noise ratio (SNR).  
Diffusion weighted imaging, DWI 
Diffusion weighted imaging was not used in this thesis but today the technique is used in 
most oncological MR protocols to distinguish normal healthy tissue from pathological and for 
evaluating treatment response. The technique refers to the assessment of the random motion 
of water molecules in tissues is hampered in high cellularity tissues and areas such as tumours 
by using diffusion weighted gradients to create contrast in MR images. Areas with hampered 
or restricted diffusion will appear with high signal intensity as bright areas on DWI images. 
The condition could also appear in tissue inflammation or in abscesses. The DWI sequence 
used is a fast T2 weighted sequence combined with diffusion gradients (b-value).  When 
using at least two diffusions gradients (two b-values), the diffusion can also be quantified 
measuring the apparent diffusion coefficient (ADC) (75). Some tissues, such as lymph nodes, 
will appear with relative impeded diffusion compared to surrounding tissues. This will 
facilitate detection of these tissues. For characterization, such as distinguishing between 
lymph node involved by malignant tissue or not, it is hazardous because of minor difference 
and overlap between diffusion in benign and malignant lymph nodes due to high cellularity in 
a normal lymph node (76). 
1.5.5 Positron Emission Tomography (18FDG) PET/CT 
Positron emission tomography (PET) is a nuclear medicine technique often referred as 
functional imaging, obtaining the metabolic and biochemical activity in the body. PET is 
based on the decay of unstable radioactive positron emitting isotopes and measures the two 
annihilation gamma photons. The most commonly radiotracer used in oncology is (fluorine 
18)fluoro-deoxy-glucose (18F-FDG) and is produced in cyclotron and have a half-time decay 
  20 
of ~100 minutes and therefore suitable for medical imaging. The FDG molecule is a glucose 
analogue where oxygen is replaced with 18-fluorine. One of the mechanisms to absorb 
glucose into the cell is via the system of active transportation proteins (GLUTs) (77). Both 
glucose and FDG are phosphorylated within the cell and glucose is used for energy 
production. FDG on the other hand is trapped and cannot move further on. Cancer cells tend 
to have elevated expression of transport proteins and higher metabolic activity and also use 
other pathways for glucose uptake than normal tissues (78). Therefore, FDG tend to 
accumulate in cancer cells. Inflammation and hyperactivity of muscles will also accumulate 
FDG due to normal increased metabolism. 
The combination of FDG-PET/CT combines anatomical information from CT and functional 
information in forms of uptake of radiolabelled substances from FDG-PET. In colorectal 
cancer imaging this examination is not part of the routine work up in primary colon cancer 
staging and mainly used before major surgery, detection of distant metastases when 
conventional imaging is unequivocal or for work up of recurrent disease (79). 
 
1.6 DIAGNOSIS IMAGING FOR STAGING OF COLON CANCER 
Accurate preoperative staging in colorectal cancer is essential for evaluating local tumour 
extent and presence of metastases for treatment planning and evaluation of prognosis. After 
local or systemic pre-operative treatment re-staging may result in altered management.  
1.6.1 CT 
The standardized work up for patients with colorectal cancer is contrast enhanced CT of the 
thorax and abdomen for evaluation of local tumour spread and presence of distant metastases. 
The main purpose of the examination is to exclude metastatic disease but it is also important 
to evaluate the local tumour extent, in particular presence of locally advanced disease to be 
able to adequately prepare and perform the surgical procedure. There are parts of the colon 
that are more challenging to evaluate due on one hand close presence to nearby organs and on 
the other hand circumferential serosal coverage. Bowel preparation prior to the examination 
is often not used and has probably little importance.  
ctT-stage 
For tumour staging with CT, the muscularis propria is not visible in the same extent as with 
MRI. For the lower T-stage is not possible to discriminate T1 and T2 tumours. To evaluate if 
the tumour is growing outside the bowel wall (T3) it is important to have perpendicular 
images over the tumour area. If the bowel wall in that area is indistinct or bulging there is a 
risk of tumour extension in the surrounding fat. If the tumour extension is limited to the 
mesocolon it is measured and classified into T3a-d. There could be other reasons for 
indistinct bowel wall than tumour due to inflammation or oedema. For anatomical reasons 
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there are parts of the colon with little amount of surrounding fat and a short distance to the 
serosa.  
ctN-stage 
No imaging modality has yet proven to accurately identify lymph nodes metastases in 
colorectal cancer. Regarding cross sectional imaging, and particular for CT, widely accepted 
criteria for assessing lymph nodes metastases have not yet been established. Various criteria 
have been used. Short axis of more than 10 mm, short-long axis diameter ratio, internal 
heterogeneity, irregular outer border, attenuation values > 100 HU, cluster of at least three 
“normal” sized lymph nodes or a various combination of those have all been used in the 
literature (80-86) (Figure 5). The diagnostic accuracy for detection of lymph node metastases 
on CT has also been analysed in a meta-analysis of eleven studies and 753 patients with a 
sample weighted sensitivity/specificity of 76/55 % respectively (87). Normal lymph nodes 
appear as homogenous oval structures with well-defined borders.  
                                 
Figure 5. Tumour in the ascending colon, pT4a+b (tumour invades directly the ileum and having serosal 
components). pN2b, lymph node with irregular outer border (white arrow) and lymph node with internal 
heterogeneity (white and black arrow). 
ctM-stage 
Distant metastases are defined as metastases localized beyond the lymph node metastases in 
the large bowel mesentery; in the paraaortic lymph nodes, peritoneum, liver, lungs, skeleton 
and brain, the latter less common. The most common metastatic sites are the liver and the 
lungs (46). If high suspicion of distant metastases on CT further investigation is needed 
according to the care flow to tailor treatment (31). On CT,  liver metastases usually appears as 
focal more or less indistinct defined low attenuating lesions separated from benign well 
defined benign cyst, which are common finding (Figure 7). For further assessment and for 
treatment planning dedicated MRI examination of the liver is offered. For indeterminate 
pulmonary nodules, a  follow up is often recommended by the MDT (31). 
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1.6.2 MRI 
The main benefit of using MRI in colorectal oncological imaging is the high soft tissue 
contrast resolution and the functional capabilities. In rectal cancer MRI has been routinely 
used since the past two decades for local tumour staging (88-91). The pelvis and in particular 
the rectum is nearly ideal for MRI examination due to its fixed location. In the colon, the 
anatomy and the course of the bowel is more complex. As in rectal cancer, an MRI of a 
colonic tumour is performed with fasting but without intra venous contrast and no other 
bowel preparations (no cleansing). The major and most important sequences are T2w 
sequences in three orthogonal planes and one high resolution sequence perpendicular to the 
bowel over the tumour. Visualization and location of the tumour can be challenging when 
using MRI specially when planning the perpendicular imaging over the tumour to assess the 
extent of the tumour within or through the bowel wall into the neighbouring tissues. Motion 
artefacts related to bowel movements or breathing are also more frequent occurring and 
challenging in the colon compared to the rectum. To reduce motion artefacts, careful patient 
instructions, surface coil positioning and spasmolytic drugs are all used. The MR procedure is 
generally more time consuming than a CT examination and often requires a radiologist on 
site to plan and monitor the examination, in particular position of slices perpendicular to the 
bowel wall at the level of the tumour. 
mriT-stage 
The bowel wall is consisted of several layers (Figure 4). The inner layer, towards the bowel 
lumen, is the mucosae and muscularis mucosae which will appear as a thin dark band on T2 
w imaging, and not always visible. The submucosa will appear as a bright band between the 
muscularis mucosae and the propria muscle. The next layer is the muscularis propria (MP) 
which appear dark on T2w imaging. This muscle is a landmark for distinguishing T2 from T3 
tumours. If this muscle layer is partially disrupted by a tumour this is a sign of a T2 tumour. 
If the layer is fully disrupted it is a sign of full thickness T2 or limited extra mural extension. 
If the tumour extends beyond the MP and extends in the surrounding fat, the tumour will be 
staged as T3 or T4a depending on whether the tumour is present on a peritonealised or non-
peritonealised surface (Figure 6). 
mriN-stage 
For nodal staging in rectal cancer, morphological criteria are used when performing MRI. If 
the lymph node (>3mm) showed internal heterogeneity and/or irregular outer border or low 
signal on T2w images it is regarded as metastasis with a reported sensitivity and specificity of 
85% and 97% respectively compared to histopathology (92). In colon cancer, there are so far 
no such adopted criteria for mriN-staging. 
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a)                                                                                                       b) 
Figure 6. T2-weighted MR images of tumour in the caecum and ascending colon. a) Axial perpendicular plane b) 
Sagittal plane. Narrow white arrows show muscularis propria as a dark band. Bold white arrows show 
extramural tumour extensions in the fat involving the anterior abdominal wall. 
mriM-stage 
MRI is particular used when focal liver lesions cannot be characterised by multiphasic CT. 
The standard protocol for liver lesions such as metastases includes morphological T1 and T2 
axial sequences, in and out of phase sequences, dynamic T1 sequences after intra venous 
contrast and DWI sequences. 
 
a)      b)                 c) 
Figure 7. Focal metastasis in the right liver lobe (white arrow). a) On CECT ill-defined low attenuated. b) 
Moderate high signal intensity on T2-weighted MRI image. c) High signal intensity on DWI image (b-value: 800 
s/mm2). 
 
Ultrasound (US) can be used for characterization of solitary liver lesions. MRI offer better 
sensitivity regarding evaluation of the number of metastases compared both CT and US. MRI 
is the standard modality for treatment planning when liver surgery is an option for curative 
treatment in CRC (93-95). 
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Further prognostic feature on MRI 
Extramural vascular invasion (EMVI) is associated with poor prognosis in rectal cancer (91, 
96). On MRI, the normal small vascular structures present with a serpiginous or tortuous 
appearance with tumour signal on T2-weighted images. A recent study reported that MRI 
could accurately predict EMVI compared to histopathology in rectal cancer (97). 
Potential circumferential resection margin 
When the potential circumferential resection margin (CRM) is involved at imaging this 
means that the tumour extends within one mm from the original embryological plane or 
affecting nearby structures or organ(s). In the colon, the CRM is the retroperitoneal fascia. 
When involved this requires modified surgical resection to achieve macroscopically tumour 
free resection (R0 resection). 
1.6.3 18FDG-PET/CT 
18FDG-PET/CT is well established as a diagnostic tool in the evaluation of patients with 
rising carcinoembryonic antigen (CEA) and suspected local recurrence or metastases of 
colorectal cancer, as shown in a recent review (79). There is not sufficient evidence to use 
18FDG-PET/CT in the primary staging unless conventional staging indicates need for 
additional information. When major surgery of locally advanced or recurrent disease is 
considered 18FDG-PET/CT can be suggested at the MDT conference (98) (Figure 8). 
a)                              b)                                         c) 
Fig 8. Recurrent disease. Metachronous tumour in the transverse colon (white bold arrow) and peritoneal 
carcinomatosis in the left side of the peritoneal cavity (white narrow arrow) on a) contrast enhanced CT (CECT), 
b) FDG-PET and c) fusion image.  
1.7 MULTIDISCIPLINARY TEAM CONFERENCES 
To optimize the management of oncological patients, multi-disciplinary team (MDT) 
management is gaining acceptance to individualize the treatment and has been shown to 
improve the oncological outcome (99). The team members represent different medical 
specialties; surgeons, oncologists, radiologists, pathologists and coordinators. CRC patients 
are individually discussed both pre- and post-operatively.  
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1.8 PRE-TREATMENT 
I colon cancer, no routine pre-treatment is performed. For some patients with metastatic 
disease or locally advanced colon cancer, preoperative chemotherapy can be given. The neo-
adjuvant treatment is discussed in section 1.10.1. 
1.9 SURGICAL MANAGEMENT 
1.9.1 Polypectomy 
Small tumours, limited to a polyp without any signs of spread through the bowel wall, to 
lymph nodes or vessels can in some patients be locally excised through a colonoscope. 
1.9.2 Conventional open surgery 
Colon cancer surgery is divided into right sided hemicolectomy, left sided hemicolectomy, 
sigmoid resection and total colectomy depending on the site of the tumour. Surgical treatment 
for colon cancer surgery should be performed in an elective setting, if possible, to obtain best 
curative and oncological outcome (100). In the emergency setting, due to bowel obstruction, 
perforation or bleeding acute interventions are sometimes inevitable. In such instances, 
limited procedures not jeopardizing the oncological outcome such as temporarily ileostomy is 
performed and leave cancer surgery to a well-planned elective setting. The general 
contemporary treatment of colon cancer is the complete mesocolic excision (CME) concept 
by surgical removal of the tumour containing segment together with local and regional lymph 
nodes within the mesocolon en bloc tying of the supplying vessels as central as possible (i.e. 
“high tigh”) (101). Surgery is performed by sharp dissection within the holy plane between 
the visceral and peritoneal fascia layers that are fused together. For colon cancer this CME 
method was introduced by Prof Hohenberger and has proven to reduce the recurrent rate and 
improve survival (102). According to the location of the tumour the surgical approach can 
either be from the medial or the lateral side. Tumours located in the flexures and transvers 
colon often requires extended dissection of the vessels and lymph node beneath the pancreas 
and gastroepiploic arcade to require a R0 dissection (103). After the tumour bearing segment 
is removed the remaining bowel ends are reconnected by sewing or staples in an anastomosis. 
In some cases, a temporary colostomy is considered if the bowel ends cannot be fused 
together or to unload the anastomosis until the bowel can be reconnected. 
1.9.3 Laparoscopic surgery 
This procedure is less invasive than open surgery. Percutaneous incisions into the peritoneal 
cavity are performed to administer camera and instruments. A laparoscopic procedure is often 
the method of choice in non-locally advanced cancers without any complicating factors. 
1.9.4 Treatment of distant metastases 
At diagnosis, approximately up to 20% of patients with colorectal cancer present with 
metastatic disease (3, 42). The most common distant metastatic site is the liver and up to 50 - 
70% of the CRC patients will develop liver metastases (41, 42). The mortality in metastatic 
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CRC when the liver is the metastatic site is primarily determined by the burden of liver 
metastases (41). If metastases, especially in the liver, are present this does not exclude the 
patient from curative treatment or to achieve hepatic tumour control. At the MDT conference, 
the most appropriate sequential treatment to surgically remove both primary tumour and 
distant metastases either at the same time or different occasions is discussed. If a two-stage 
procedure is preferred, it is also discussed whether to remove the primary tumour or the 
metastasis/metastases first. Surgical treatment (removal) of liver metastases is the only 
curative treatment and increases the chances for prolonged survival (104, 105). The 
possibility of surgically removal of liver metastases is dependent on the size of the future 
liver remnant is adequate (104). If the liver metastases are not primarily resectable, local 
treatment of liver metastases can also be performed by minimally invasive procedures as 
local radiofrequency ablation (RFA), microwave ablation, cryoablation or 
chemoembolization or local chemotherapy (106, 107). For some patients or in controlled 
trials systemic chemotherapy can downsize the metastasis for later removal (108). For 
metastases in the lungs, treatment with chemotherapy and/or surgical resection is feasible 
according to national guidelines (31). 
1.9.5 Treatment of peritoneal carcinomatosis (PC) 
Beyond the mechanisms of haematogenous and lymphatic tumour spread, colon cancer 
frequently cause transcoelomic spread from serosa involvement into the visceral peritoneum 
at the site of the tumour and may cause PC and have been shown in up to 3-28% in CRC 
patients (109). PC can be either limited outside the serosa of the bowel or extensive with 
tumour spread at different sites in the peritoneal cavity. Peritoneal tumour spread can 
potentially be surgically removed by parietal and visceral peritonectomy so called 
cytoreductive surgery (110). The treatment today combines meticulous surgical resections of 
peritoneal surfaces and intraperitoneal chemotherapy (HIPEC) (111-113). Pre-operative CT 
for staging is generally performed for quantifying the peritoneal cancer index (PCI) and 
exclude presence of distant metastases. Difficult areas for staging and treatment are the small 
bowel mesentery, retroperitoneum, the ligaments around the liver. The accuracy of pre-
treatment PCI staging with CT as compared to surgical PCI staging is moderate (112, 114). 
Often diagnostic laparoscopic procedures are performed before to avoid unnecessary 
laparotomy. 
1.10 ONCOLOGICAL TREATMENT 
The main effect of the chemotherapy is to attack cells with rapid cell growth (i.e. cancer cells) 
and there are different types of chemotherapy with different ways of interfere with or end the 
cell cycle forming new cancer cells. The side-effects of chemotherapy depend on the type of 
drug used, administration (intra venous or oral) and treatment duration. Other cells in the 
body with rapid cell growth and divides quickly are bone marrow, the epithelium in mouth 
and GI tract and hair follicles could also be affected during chemotherapy. Usual side-effects 
symptoms are fatigue, increased risk of infection, mouth sores, nausea and vomiting, 
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diarrhoea and hair loss. For some patients, the side effects are too severe to continue the 
treatment. 
1.10.1 Neoadjuvant treatment 
Neoadjuvant chemotherapy has demonstrated effect and are well established in other 
malignant tumours such as in rectal, oesophagus, gastric and breast cancer (115-118). The 
theoretical benefits of neoadjuvant treatment are better oxygen and blood supply prior 
curative surgery and post-operative conditions compared to the adjuvant treatment setting. In 
high risk rectal cancer, chemotherapy or chemo radio therapy and TME surgery has been 
shown to improve the disease free survival and mortality (119). 
In colon cancer, there is not yet established consensus regarding the role of neo adjuvant 
therapy. In patients with metastatic disease (stage IV) colon cancer, the current treatment is 
chemotherapy for down staging prior eventual surgery (31). 
Neoadjuvant treatment in this setting is at question and is evaluated in several ongoing trials. 
The FOxTROT (Fluoropyrimidine Oxaliplatin and Targeted Receptor Pre-Operative 
Therapy) trial includes patients with tumour stage T3cd and T4 into different regimes of 
chemotherapy (OxMdG, Oxaliplatin, I-folonic acid, fluorouracil) in a randomized controlled 
trial results. One of the hypotheses as well as preliminary experience is that a lower portion of 
patients require adjuvant treatment if neoadjuvant treatment has been administered (120). A 
similar study including patients with colon cancer with tumour stage T4 and T3cd tumours 
and no metastases or PC could after neoadjuvant chemotherapy demonstrate a significant 
reduction in tumour size, EMVI, number and size of enlarged lymph nodes using CT in re-
staging (121). Additionally a recently published study showed some benefit of neoadjuvant 
chemotherapy in T4b patients but not in T3 and T4a (122). 
1.10.2 Adjuvant treatment 
Adjuvant treatment is chemotherapy after curative colon cancer surgery. The intention with 
treatment is to kill micro metastases and reduce the risk of cancer recurrence. The adjuvant 
treatment is based on the histopathological findings such as the pTNM staging and 
assessment of the other prognostic adverse features. 
For stage I colon cancer there have been so far no shown benefit of additional post-surgical 
chemotherapy treatment. The adjuvant treatment today is offered to stage III patients which 
reduces the risk of death by 10-15% compared with no adjuvant treatment after curative 
surgery (123). For some stage II patients with other risk or prognostic adverse features (risk 
factors) adjuvant treatment can be offered. Those risk factors may consist of tumour stage T4, 
few lymph nodes examined by pathologist, CRM involvement, low differentiated tumour, 
tumour growth in veins or nerves or emergent surgery. Stage II is a heterogeneous group and 
is often divided in low and high risk group depending on number of risk factors. The risk of 
recurrence and death in the stage II low risk group is 20% and for the high risk group 30-40% 
and for stage III the risk is 40-60% (31). In a recent systematic review and meta-analysis the 
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five-year disease free survival (DFS) for stage II not treated with adjuvant therapy was 
around 80% and for stage III, treated with adjuvant therapy 64% (124). 
5-Flourouracil (5-FU) has been used for decades in colon cancer and is used for adjuvant and 
palliative setting and has rather moderate side effects. Modern recommendations regarding 
chemotherapy includes a combination of 5-FU with oxaliplatin for high risk patients. 
In locally advanced colon cancer, chemotherapy can be used to downsize the tumour and to 
relieve patient’s symptom and facilitate the surgical procedure. 
1.10.2.1 Treatment of metastatic colon cancer 
Treatment of metastatic colon cancer has developed and is customized for the individual 
treatment purpose. About 20% of the patients with colorectal cancer will present with 
metastatic disease at the time of diagnosis. Surgical resection of liver and lung metastases can 
be performed more than one time and improve 5-year survival for this patient group (125, 
126). 
Chemotherapy is not only based on 5-FU but also irinotecan and oxaliplatin are used in 
metastatic disease. New treatments with targeted antibodies effecting the endothelial growth 
factor and epidermal growth factors and tyrosinkinase inhibitors have also been introduced 
(31). 
Often a combination of chemotherapy and targeted therapy is given to enhance the treatment. 
Targeted therapy can also be given alone when conventional chemotherapy does not have any 
effect. Targeted therapy attacks the cancer cells by for an example affecting growth factors to 
inhibit angiogenesis. Patients with mutation in the KRAS-gene are likely to be non-
responders to some targeted adjuvant chemotherapy such as cetuximab and panitumumab 
(98, 99). Treatment of metastatic disease is complex and delicate and must involve a 
specialised oncologist. 
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2 AIMS OF THESIS 
General Aim 
To investigate new cross sectional imaging technology for detection and staging of colonic 
tumours. 
2.1 PAPER I 
“Polyp detection with MDCT: a phantom-based evaluation of the impact of dose and spatial 
resolution.” 
The aim of study was to evaluate the impact of radiation dose and axial spatial resolution on 
detection of colonic polyps using 4-MDCT in vitro. 
2.2 PAPER II 
“Potentials of high resolution magnetic resonance imaging versus computed tomography for 
preoperative local staging of colon cancer.” 
The aim of study was to compare high resolution MRI with standard preoperative CT 
protocol in distinguishing locally advanced from not locally advanced colon cancer. 
2.3 PAPER III 
“Assessment and diagnostic accuracy of lymph node status to predict stage III colon cancer 
using computed tomography.” 
The aim of the study was to assess whether the number of lymph nodes, their anatomical 
location and distribution, size, size ratio, internal heterogeneity, irregular outer border and 
attenuation values on preoperative CT, either alone or in combination, were predictive for 
stage III disease in colon cancer. 
2.4 PAPER IV 
“Morphological predictors for lymph node metastases on computed tomography in colon 
cancer.” 
The aim of the study was to assess the accuracy and interobserver variation for morphological 
criteria for lymph node characterization on preoperative CT, either alone or in combination 
for prediction of stage III disease in colon cancer 
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3 PATIENTS AND METHODS 
3.1 PAPER I 
 
“Polyp detection with MDCT: a phantom-based evaluation of the impact of dose and spatial 
resolution.” 
This phantom study was performed during the early era of computed tomographic 
colonography (CTC) when numerous studies proposed different CT protocols for patients 
with symptoms or in the screening situation (127-131). To reduce the radiation dose, to the 
patients several attempts were performed to create low-dose protocols (130, 132). For CT 
procedures in general and in screening settings in particular, the radiation dose to the patient 
has to be taken into account. The radiation dose on CT depends on the tube voltage, tube 
current, pitch factor and the collimated beam size. Despite technological advances, there will 
always a trade-off between the radiation dose, spatial resolution and image noise. 
To simulate the large bowel, twenty-four latex phantoms at a length of 50 cm contain 
artificial polyps of different sizes and shapes were constructed. At every 3-5 cm, a fold 
(artificial haustrae) yielding various degrees of distention was simulated to create inner 
diameters varying from 1 to 7 cm (Figure 11). 
A total of 240 synthetic polyps were made from the latex material. The polyps were divided 
into three size groups; x, y and z (diameter; (x) 0-2, (y) 2-5 and (z) 5-10 mm) and were 
categorised into four shape groups: pedunculated, broad-based, ulcerated or depressed and 
sessile or flat. The polyps were evenly distributed among the size groups, resulting in 80 
polyps of each size interval. There was also an even distribution of polyps among the 
different shapes, resulting in 20 polyps of each shape in each size interval. 
               
      Fig 9.                   Fig 10. 
Figure 9. Axial CT scans (2D) show polyps of different shapes. 1, pedunculated; 2, broad-based; 3, ulcerated or 
depressed with elevated margins; and 4, sessile or flat.  
Figure 10. Endoluminal views from CT scans (3D) of colon polyps of different shapes. 1A and 1B, 
pedunculated; 2A and 2B, broad-based; 3A and 3B, ulcerated or depressed with elevated margins; and 4A and 
4B, sessile or flat. 
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The colon phantoms were submerged in a water tank and scanned on a 4-channel multi slice 
CT scanner using 12 protocols with various settings of slice thickness, pitch and X-ray tube 
current (Table 3). The images were independently evaluated by three radiologists using axial 
2D multiplanare reconstruction images and a 3D surface-rendering technique (so called “fly-
through”). 
The experimental and evaluation protocols were designed to study the effects of the tube 
current setting, pitch factor and nominal slice thickness on the detection of colonic polyps of 
different size and shape hence these parameters are likely to have a significant impact on 
polyp detection. Although the kilo voltage (kV) setting could also influence detection and 
will impact the dose delivered to the patient, it was excluded from this study because all 
clinical experience with abdominal CT at our clinic is based on 120 kV data. 
Experimental CT scanning protocol 
The experimental protocol included a series of 12 CT scanning sequences. An outline of the 
protocol is given in Table 3. The tube potential was kept constant at 120 kV in all sequences. 
Estimates of the dose-length product (DLP) were calculated from measured normalized CT 
dose index-weighted (nCTDIw) values for the different beam collimations used - that is, 5 (or 
4 × 1.25), 10 (4 × 2.5), and 15 (4 × 3.75) mm, respectively. The standard CT sequence used 
for colonography in the clinic was based on the following settings: 100 mA, 1.5 pitch, 2.5-
mm slice thickness (CT8 in Table 3). 
 
Table 3. Twelve CT protocols with different slice thickness, beam collimation, table feed, pitch factor, scanning 
time and tube current resulting in different radiation dose (DLP). 
The DLP of the standard sequence was defined as the 100% dose level. The ratio of DLP for 
any given experimental sequence and DLP of the standard sequence was calculated and was 
referred to as the “relative DLP” in Table 3. The relative DLP values were in the range of 40-
486% of the standard sequence, and the corresponding tube current values were calculated. 
Because of restrictions in the scanner software, small deviations in the tube current settings 
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from those calculated had to be accepted for some sequences. The corresponding effective 
dose values were calculated (Table 3). 
A total of 24 colon phantoms (12 CT scanning sequences × 2 colon phantoms per radiologist 
and sequence) were constructed. The colon phantoms were submerged in a tank constructed 
from polymethylmethacrylate and filled with water (Figure 11). The dimensions of the tank 
are representative of the object size for adult bowel CT examinations (length 40 cm, width 25 
cm, height 19.5 cm). The scanning procedure included two colon phantoms in each 
acquisition.  
                 
Figure 11. A typical setup with two colon phantoms, inflated with air and submerged in the water tank. 
To simulate the clinical CTC examination setting, the observers were blinded to the number 
and shape of the polyps in the colon phantoms. In addition, the same observer evaluated a 
specific phantom only one time. Finally, the total number and size of the polyps to be 
evaluated for each CT sequence were kept constant. On the basis of these requirements, three 
criteria were defined and applied to each of the 12 different CT sequences. The first criterion 
was that evaluations should be performed independently by three observers with similar CTC 
experience. The second criterion was that six different colon phantoms should be included 
(two for each radiologist). The third criterion was that a total of 60 polyps (20 in each size 
group) should be distributed among the six phantoms. 
Three radiologists with at least 2 years of experience in CTC were chosen to participate as 
observers in the study and were informed of the different polyp shapes and size intervals prior 
to data evaluation. The 24 phantoms were distributed in four groups, each with six phantoms. 
Each phantom group was then used to acquire data for three CT scanning sequences. The 
rotational scheme of the phantoms in each group is shown in figure 12. After completion of 
the study, each radiologist had examined all 24 phantoms. 
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Figure. 12. Diagram shows rotational scheme of 24 phantoms used during data acquisition. R1, R2, and R3 refer 
to radiologists 1, 2, and 3, respectively. Colon phantoms are displayed as rectangular boxes. The reference 
number of phantom used to acquire data for a given sequence is indicated in the left subsection of each box. The 
numbers in the right subsection refer to the number of polyps in size groups X, Y, and Z, respectively. For each 
scan sequence, the number of polyps in each size group was kept constant and equal to 20. 
 
The impact of residual fluid on polyp detection in the colon lumen was evaluated by 
rescanning phantoms in group 4 (i.e., sequences CT1, 7, and 10) after the addition of some 
water. The water filled approximately 20-30% of the lumen volume. The submerged polyps 
were not visible with the viewing settings used in the evaluations. To complete the 
experimental protocol, a total of 45 data acquisitions were performed: 36 (12 × 3) with 
phantoms having no water inside and nine (3 × 3) with phantoms partially filled with water. 
The study design included a total of 720 polyps (12 × 60) to be evaluated in air filled colon 
phantoms without water and an additional 180 polyps (3 × 60) in phantoms partially filled 
with water. 
Evaluation Protocol 
The CT scans were evaluated on a dedicated workstation (Advantage Windows 3.1, GE 
Healthcare) using a software tool (Navigator [version 2], GE Healthcare) using the same 
viewing settings of the workstation monitor as those used during clinical CTC examinations 
(window width, 1600 HU; window level, 400 HU). Two different evaluation methods were 
used: axial images were displayed in three orthogonal directions (referred to as “2D 
multiplanare reconstruction (MPR) technique”) and virtual colonoscopy images, yielded by a 
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3D surface-rendering technique (referred to as “fly-through” 3D technique”), were shown. 
Using the 2D MPR technique, the number of polyps in each size group (x, y, z) was defined 
for each colon phantom. Using the 3D technique, the total number of polyps of each of the 
four defined shapes, independent of size, was detected using forward and backward “fly-
through” of the phantom. No polyp matching was done. If the number of polyps registered 
for a given shape exceeded the correct number, those in excess were regarded as misclassified 
and all others were regarded as correctly classified. 
 
3.2 PAPER II  
“Potentials of high resolution magnetic resonance imaging versus computed tomography for 
preoperative local staging of colon cancer.” 
Patients with a biopsy proven colon cancer were admitted from the surgical department for 
CT of the abdomen and chest X-ray as well as MRI during the years 2005-2009. Forty-nine 
patients were prospectively enrolled in the study after approval of the regional ethical review 
board. After exclusion criteria, the final cohort consisted of twenty-eight patients with 29 
tumours. 
The pre-operative MRI examination were performed on a 1.5 T MRI scanner in supine 
position using a cardiac five-channel surface receiver coil. After a coronal localizer with a 
Half-Fourier T2-weighted single-shot sequence for tumour localization, high-resolution, 
respiratory triggered T2-weighted turbo spin-echo sequences (TR 1800, TE 120 ms) were 
performed covering the tumour area in at least three different orthogonal planes; axial, 
sagittal, and coronal as well as a perpendicular sequence to the lumen of the bowel (true axial 
imaging). The voxel size in the high resolution sequence was (0.5–0.6 x 0.5–0.8 x 3.0 mm) 
with a field of view of 375 x 262 mm and 255 x 217 mm. 
The preoperative CT examinations were from different radiological units and were performed 
with a range of different CT-scanners from single slice technology up to 64-slice helical CT 
scanners with intravenous contrast media in the portal venous phase. The saved imaging data 
from these scans included images with a reconstructed section thickness that varied between 
5 and 8 mm.  
The imaging examinations were retrospectively and independently evaluated by two 
experienced GI radiologists in reading abdominal MR and CT examinations and evaluated at 
different occasions making sure that MR and CT examination from the same patient could 
not be recognized and were blinded to one another and to the histopathological reports. The 
examinations were assessed according to the Tumour Node Metastasis classification (TNM) 
6 edition according to UICC (133). 
Tumour stage was classified as not locally advanced, with maximum extramural tumour 
extent was less than 5 mm (T0-T3ab) and locally advanced, with extra mural tumour extent 
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>5mm or tumour stage T4 (T3cd-T4). Nodal stage and presence of extra mural vascular 
invasion (EMVI) were also evaluated. 
The surgical procedure was performed by total mesenteric excision including central ligation 
of the supplying arteries and draining veins together with a maximum of harvested 
mesenteric lymph nodes according to established techniques of complete mesocolic excision 
(CME) (102, 134). The surgical specimens were processed according to local work-up 
routines for colon cancer where tumour sections were selected for histopathological analysis 
and dissection of the pericolic fat in the search for lymph nodes was performed. The 
histopathological slides were retrospectively reviewed by a consultant GI pathologist. 
Descriptive statistics using sensitivity and specificity and observed agreement (accuracy) was 
used to assess T-stage (not locally advanced vs local advanced), N-stage, and EMVI for both 
MRI and CT compared to histopathology. To compare the inter-observer agreement between 
the both observers and both modalities Kappa statistics according to Cohen was calculated 
and was categorised as poor agreement, fair, moderate, good and very good according to 
Kappa (k) values, 0-0.20, 0.21-0.40, 0.41-0.60, 0.61-0.80 and 0.81-1.00, respectively. 
 
3.3 PAPER III 
“Assessment and diagnostic accuracy of lymph node status to predict stage III colon cancer 
using computed tomography.” 
From the Swedish colorectal cancer registry (SCRCR), 483 consecutive patients having a 
histology proven colon cancer and operated between the years 2008 and 2011 and examined 
with abdominal CT (64 detector CT-scanner) with intravenous contrast before surgery at our 
institution were identified. 
After exclusion, a cohort of 119 patients with histologically proven colon cancer without 
metastases and stage IV were included. There were 63 women and 56 men with a median age 
of 69 (range 32-91 years). All patients had preoperative investigations with CT of the 
abdomen with intravenous contrast on one of four different 64 slice CT scanners. After the 
examination, reformatted images in axial, coronal and sagittal planes with 5 mm thickness 
(increment 2.5 mm) were routinely generated together with the original (thin slices) 0.625 
mm images. 
CT evaluation 
All CT examinations were retrospectively reviewed by one radiologist and blinded for the 
histology and surgical reports. Examinations were assessed according to a dedicated 
evaluation protocol. All measurements and assessments were performed on a SECTRA 
Workstation IDS7 (version 15.1.14.41) using the 5 mm reformatted images with 2.5 mm 
increment. The original thin slices (0.625 mm) were used for detection of small lymph nodes 
(≤4 mm). 
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Anatomical distribution 
The colonic mesentery, 5 cm oral and aboral from the tumour site, was divided in three 
anatomical regions (region 1–3), as a modified variant of the guidelines from the Japanese 
Society for Cancer in the Colon and Rectum (135). Region 1 was defined as the region most 
adjacent to the tumour (+/−5 cm) and 3 cm proximal along the vessels to the branch artery 
divides covering the pericolonic and marginal lymph nodes. Region 3 was defined as the 
most proximal part of the mesentery including the undivided mesenteric artery from the aorta 
(proximal lymph nodes). Region 2 was defined as the region between region 1 and 3 (Figure 
13).  
                                        
Figure 13 Anatomical location of lymph nodes regions 1-3. T=Tumour in the ascending colon and sigmoid colon 
respectively. SMA=Superior mesenteric artery. IMA=Inferior mesenteric artery. 
Number, size and size-ratio of lymph nodes 
All lymph nodes ≥2 mm in size were separately registered in total and in each anatomical 
region. For lymph nodes ≥4 mm in shortest diameter, the short axis and the long axis were 
also separately measured and the ratio between the short and long axis diameter was 
calculated. The size ratio (ratio between two orthogonal (short/long) axis diameters) was used 
to test whether a more rounded shape was predictive for metastasis. A >0.8 ratio between 
diameter was used as cut off point according to a previous study (136). The presence of a 
cluster (within a range of the lymph node diameter) of three or more lymph nodes was also 
separately noted in every region. 
Internal heterogeneity and irregular outer borders of lymph nodes 
As possible morphological predictors of lymph node metastases, internal heterogeneity (IH, 
mixed attenuation within the lymph node) as well as the irregular outer border (IOB, 
indistinct demarcation of the lymph node) were evaluated both on reformatted and thin 
sections (Figure 14 and 15). 
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Figure 14.   Figure 15. 
Figure 14. Coronal reformatted (5 mm section post iv contrast portal phase) CT image illustrating the appearance 
of 10 × 15 mm lymph node (white arrow) in region 1 with internal heterogeneity and well defined borders in a 
patient with pT3 tumour in the ascending colon. At histopathology, 4 metastatic lymph nodes out of 43 were 
harvested. 
Figure 15. Transaxial reformatted (5 mm section post iv contrast portal phase) CT image illustrating the 
appearance of a 7 × 7 mm mesocolic lymph node (white arrow) in region 2 with irregular outer border and 
internal heterogeneity in a patient with a pT3 tumour in the sigmoid colon with 1 metastatic lymph nodes out of 
16 harvested at histopathology. 
 
Attenuation values 
Attenuation measurement of each lymph node in the portal venous phase and, when 
available, in the arterial phase was also performed. All density measurements (using HU) 
were performed by placing as large a region of interest (ROI) as possible (>2 mm2) on the 
lymph node in the portal venous phase and in the arterial phase when available. Attenuation 
values of ≥50 and ≥100 HU in the portal venous phase were separately noted as well as ratio 
portal venous/arterial phase. Inhomogeneous contrast enhancement as indicative for tumour 
involvement was distinguished from either presence of a fatty lymph node hilum or a contrast 
filled vessel in the vicinity of a lymph node. 
Surgery 
All patients in the study were operated in an elective setting and according to colorectal 
surgery praxis (TME). The resection of colon cancer was made by clear lateral margins, 
resection of the loco-regional lymph node bearing mesentery. 
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Histopathology 
Histopathology was performed according to standard procedures at the university hospital 
pathology department by a specialised GI pathologist (initially using TNM version 6 and later 
TNM version 7) (33, 133). From the pathologists’ report the T- and N-stage, the total number 
of harvested and metastatic lymph nodes served as reference standard. 
Statistics 
Descriptive statistics were applied to the different lymph node characteristics calculating 
sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and 
Odds ratio for the prediction of stage III disease. Significance level was set to p ≤ 0.05 when 
using Mann-Whitney U test. Univariate and multiple logistic regression analyses were used 
for categorical data. Receiver operating characteristics (ROC) and area under the curve 
(AUC) were used to compare different lymph node size cut off values as predictor for 
malignancy. 
3.4 PAPER IV 
“Morphological predictors for lymph node metastases on computed tomography in colon 
cancer.” 
From the results from paper III a validating study using the morphological criteria internal 
heterogeneity and irregular outer border as predictors for lymph node metastases with CT 
was performed. 
The patients were included and examined at Danderyd University Hospital, Stockholm, 
Sweden. Prior to initiation of the study a fixed examination protocol for CT and for reporting 
surgical and histopathological findings had been established. 
All patients scheduled for surgery for histopathology proven colon cancer (adenocarcinoma) 
from February 2012 to December 2014 were included in the study. Informed consent was 
obtained from each patient before entering the study. 
Patients were routinely scheduled for CT for screening of metastatic disease and for 
assessment of the primary tumour. Demographic data, pre-and-postoperative variables, 
carcinoembryonic antigen assay (CEA) (ref <5 μg/l), tumour location were recorded. In total 
112 consecutive patients were enrolled. Eighteen patients were excluded due to CT 
examination not fulfilling study protocol or presence of distant metastases.  
The remaining cohort of patients (n=94) comprised of 45 women and 49 men with a median 
age of 72 (range 45-90) years. 
Computed tomography 
All CT examinations included abdomen/pelvis and thorax with intravenous contrast in portal-
venous phase using a 64 channel multislice CT scanner (GE Light Speed-VCT). Original 
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images were reconstructed to 5 mm slice thickness with 1 mm overlap (interval 4) and axial, 
coronal and sagittal MPRs were routinely generated together with the original (thin slices) 
0.625 mm images. 
CT evaluation 
All CT examinations were retrospectively, independently reviewed by two GI-radiologists 
with more than 20 years of experience in cross sectional imaging of colorectal cancer and 
blinded to all clinical information including tumour location but except the inclusion criteria. 
Examinations were assessed according to a dedicated evaluation protocol. In case of no 
visible tumour in the colon, the tumour T-stage was assessed as T0. Both observers assessed 
tumour location (caecum, ascending colon, hepatic flexure, transverse colon, splenic flexure, 
descending colon and sigmoid colon), tumour stage into not locally advanced (T0-T3ab) and 
locally advanced (T3cd and T4). The tumour stage T0 was referred into the tumour stage (T0-
T3ab) group for further analyses. The assessment of lymph node status (N0/N+) was limited 
to three morphological criteria in line with paper III (137); a,  internal heterogeneity within at 
least one lymph node (IH) b,  irregular outer border (IOB) and c, combination of the two 
criteria, so called combined criteria (Figure 16). 
                                                     
Figure 16. Schematic description of the four different morphological lymph node features on CT. a) Normal 
lymph node, b) Lymph node with internal heterogeneity, c) Lymph node with irregular outer border, d) Lymph 
node with both internal heterogeneity and irregular outer border. 
All measurements and assessments were performed both using the 5 mm reformatted images 
and the original thin slices (0.625 mm), the latter primary for detection of small lymph nodes 
(≤5 mm) but were also in some cases additionally merged into 2 and 3 mm slice thickness. 
All patients in the study were operated in a curative elective setting and according to 
colorectal surgical praxis. Histopathology was performed according to standard procedures at 
the university hospital pathology department by a specialised GI pathologist according to 
TNM version 7 and served as reference standard. 
Statistical analysis 
Descriptive statistics were applied to the different tumour stage and lymph node 
characteristics calculating sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) for the prediction of stage III disease. Statistical significance 
level was set to p ≤0.05. Inter observer variation was classified using Cohens Kappa statistics. 
Data were evaluated using statistical analysis software, IBM SPSS Statistics (Version 24). 
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4 RESULTS 
4.1 PAPER I 
“Polyp detection with MDCT: a phantom-based evaluation of the impact of dose and spatial 
resolution.” 
Effect of Radiation Dose on Polyp Detection Rate 
The dependence on radiation dose was similar for both evaluation techniques (2D and 3D), 
with improved detection rate at a higher dose. For the standard sequence (CT5-8; 2.50-mm 
slice thickness, 1.5 pitch), the efficiency in detecting polyps of all sizes decreased from 
approximately 70% at 100% DLP (100 mA) to 55% at 40% DLP (40 mA) (Figure 17). 
 
                       
Figure 17. Bar graph showing percentage of detected polyps as function of dose-length product (DLP) using the 
spatial resolution of the standard protocol. Black bars = 2D multiplanare reconstruction technique, striped bars = 
3D fly-through technique. 
 
The results of splitting the 2D evaluations of figure 17 into the different polyp size groups are 
displayed in figure 18. At all DLP levels, the detection rate increased for larger polyps. For 
instance, at 60% DLP (relative to the standard protocol), approximately 20% of the smallest 
polyps were detected, with the detection rate increasing to almost 80% for medium-sized 
polyps and reaching 90% for the largest polyps. 
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Figure 18 Graph shows percentage of detected polyps of different sizes as a function of dose-length product 
(DLP), which was obtained from data with the same spatial resolution as standard protocol. ▪ = polyps > 5 mm; 
⊠ = 2- to 5-mm polyps; • = 0- to 2-mm polyps. 
Effect of Axial Spatial Resolution on Polyp Detection Rate 
The axial spatial resolution - i.e. the slice thickness and the pitch factor - significantly 
affected the detection rate of polyps. When the radiation dose (DLP) was kept constant and 
equal to that of the standard sequence (2.5 mm slice thickness, 100 mA, 1.5 pitch), the 
highest detection rate of polyps larger than 2 mm was obtained using the sequence with 1.25 
mm section thickness and 0.75 pitch, followed by the sequence with 1.25 mm slice thickness 
and 1.5 pitch (2D MPR technique). This is despite the significantly reduced tube current 
settings used with the narrower slice sequences to balance DLP (40 and 80 mA, respectively). 
The results are shown in figure 19.  
                  
Figure 19. Graph shows percentage of detected polyps as a function of polyp size for different settings of slice 
width and pitch factor. Radiation dose (i.e., dose-length product) was kept constant and equal to standard 
sequence. Black bars = slice width of 1.25 mm and pitch of 0.75, gray bars = slice width of 1.25 mm and pitch of 
1.5, striped bars = slice width of 2.5 mm and pitch of 1.5 (standard protocol), white bars = slice width of 3.75 
mm and pitch of 0.75. 
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Effect of Residual Fluid on Polyp Detection 
A common challenge during CT examination of the colon is the presence of residual liquid 
and stool. As we previously mentioned, the effect of residual content on polyp detection was 
simulated by the addition of water in phantom group 4 (Figure 20). 
 
                           
Figure 20. Graph shows detection rate of polyps in phantoms with and without water for three CT sequences. 
CT_1 used slice width of 1.25 mm and pitch of 0.75 (dose-length product [DLP], 100%). CT_7 used slice width 
of 2.5 mm and pitch of 1.5 (DLP, 80%); CT_10 used slice width of 3.75 mm and pitch of 0.75 (DLP, 60%). 
Black bars = 2D multiplanare reconstruction (MPR) technique, white bars = 2D MPR technique with water, gray 
bars = fly-through technique, striped bars = fly-through technique with water. 
Shape Analysis 
The evaluation of polyp shape yielded small differences between the CT sequences with 
regard to misclassified polyps, and the number of such polyps was always three or fewer per 
CT sequence (≤ 5% of all polyps) for sequences with no added water. For sequences with 
water added to the phantom, the number of misclassified polyps increased substantially and 
resulted in between seven and 11 misclassified polyps (up to 18%). The misclassified polyps 
in phantoms containing water were always registered in polyp shape group 2 (Figures 9 and 
10), indicating that those were most likely water drops attached to the phantom wall. 
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4.2 PAPER II 
“Potentials of high resolution magnetic resonance imaging versus computed tomography for 
preoperative local staging of colon cancer.” 
Six out of 29 tumours were located in the cecum, ten in the ascending colon, five in the 
transverse colon, and eight in the sigmoid colon. 
In 6 out of 28 patients involvement of neighbouring organs or potential resection margin was 
indicated by prospective evaluation of MR images and the surgical procedure in these cases 
was extended. In four of these patients, tumour infiltration of (a) neighbouring organ(s) or 
structure(s) was also suspected at surgery but could not be confirmed by histopathology 
(Figure 21). 
               
Figure 21. Sagittal a) MRI and b) CT images of a right-sided locally advanced tumour showing involved 
retroperitoneal dorsal surgical margin (Gerotas fascia). In this case surgery was extended due to imaging 
findings  
 
In three of these six patients, resected structures such as the abdominal wall, perinephric fat, 
or Gerotas fascia were not mentioned in the histopathological report and could not 
retrospectively be confirmed. In two other patients, the MRI examination postulated a high 
grade of suspicion regarding serosa involvement, which also was noted at surgery but could 
not be verified at histopathology. 
Retrospective image analysis 
T-stage 
Surgical and histopathological findings revealed that six out of 29 patients had T4 tumours 
seven patients T3 cd, eight T3 ab, and eight T2 tumours. 
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The correlation between T-stage assessed by MRI and CT by observers 1 and 2 and 
histopathology is shown in table 4. For MRI, observer 1 was able to identify 10/13 patients 
with locally advanced tumours and understaged 3/13. Observer 2 was able to identify 12/13 
pathologically proven locally advanced tumours by MRI, only understaging one tumour. For 
CT, observers 1 and 2 were both able to predict 9/13 locally advanced tumours, understaging 
four tumours. Observed agreement (accuracy) for MRI and CT was 0.90 and 0.82, 
respectively. Inter-observer agreement (Kappa statistics) for MRI was 0.79 (95% confidence 
interval (CI), 0.56-1.00; p<0.001) and for CT 0.64 (95% CI, 0.36-0.92; p<0.001). 
 
Table 4. Summary statistics of tumour staging with MRI and CT by observer. 
 
N-stage 
Seven patients had local lymph node metastases according to histopathology. Of those, four 
had N1 disease and three had N2 disease. The correlation between the N-stage as assessed by 
MRI and CT by observers 1 and 2 and histopathology is shown in table 5. 
The presence of local metastatic lymph nodes was correctly predicted in 6/7 cases by both 
observers with MRI and in 4/7 cases (observer 1) and 3/7 cases (observer 2) with CT. The 
presence or non-presence of metastatic lymph nodes was predicted in 21/29 and 20/29 with 
MRI by observer 1 and observer 2, respectively, and 21/29 and 21/29 with CT. Observed 
agreement (accuracy) for MRI and CT was 0.55 and 0.86, respectively. Inter-observer 
agreement for MRI kappa was 0.10 (95% CI, -0.26-0.46; p=0.92) and for CT 0.66 (95% CI, 
0.35-0.96; p<0.001). 
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Table 5. Summary statistics of nodal staging with MRI and CT by observer. 
 
EMVI 
Out of 27 evaluable cases, eight cases (30%) had local vascular invasion according to 
histopathology.  
Six of eight cases were predicted by MRI by both observers and 3/8 by CT by both observers. 
The correlation between histopathology and extramural venous invasion as assessed by MRI 
and CT (by observers 1 and 2) is shown in table 6. 
Observed agreement (accuracy) for MRI was 0.89 and for CT was 0.74. Inter-observer 
agreement Kappa statistics for MRI and CT was 0.76 (95% CI, 0.50-1.00; p<0.001) and for 
CT 0.22 (95% CI, -0.19-0.62; p=0.117). 
 
Table 6. Summary statistics of extramural venous invasion with MRI and CT by observer. 
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4.3 PAPER III 
“Assessment and diagnostic accuracy of lymph node status to predict stage III colon cancer 
using computed tomography.” 
Histopathology 
Thirty-nine out of 119 patients had lymph node positive (stage III) disease (28 patients N1 
and 11 patients N2). According to histopathology 80 patients were stage I-II and 39 were 
stage III (Table 7).  
Characteristics Number (%) 
Sex (female/male) 63/56 
Age (median) 69 (32-91) 
    
Histopathological evaluation   
Tumour localization   
Caecum 23 (19%) 
Ascending colon 22 (18%) 
Hepatic flexure 8 (7%) 
Transverse colon 11 (9%) 
Splenic flexure 4 (3%) 
Descending colon 6 (5%) 
Sigmoid colon 45 (38%) 
    
Tumour Stage   
T1 10 (8%) 
T2 16 (13%) 
T3 93 (78%) 
    
Positive lymph node status   
T1 tumours 2/10 (20%) 
T2 tumours 2/16 (12%) 
T3 tumours 35/93 (38%) 
    
Stage   
Stage I 22 (18%) 
Stage II 58 (49%) 
Stage III 39 (33%) 
    
Lymph nodes, total number   
Harvested lymph nodes PAD 2542 
Positive lymph nodes PAD 123 
    
CT evaluation   
Detected lymph nodes ≥4 mm/tot 442/1312(34%) 
Region 1 261/835 (31%) 
Region 2 161/389 (41%) 
Region 3 20/88 (23%) 
Table 7. Demographics table of 119 patients/tumours.  
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The median time interval between pre-operative CT examination and surgery was 28 days 
(range 4-59 days), mean 29 days (standard deviation 13 days). A total of 2542 lymph nodes 
were harvested (median 19 lymph nodes/patient, range 4-69) and of those 123 were assessed 
as metastases (median, 2 lymph nodes/patient, range 1-10). Whether TNM 6 or TNM 7 was 
used did not affect these figures. 
CT evaluation 
Number, anatomical distribution, size and size-ratio of lymph nodes 
At CT, most of the lymph nodes were located in region 1. Region 2 had higher proportion of 
lymph nodes ≥4 mm (41%) compared to the other regions (Table 7). The mean number of 
lymph nodes found was 7.2 for pT1 tumours, 8.6 for pT2 tumours and 11.8 for pT3 tumours 
(not shown in Table). 
Evaluation of lymph nodes 
Using size thresholds of ≥4, 5, 6, 7, 8 and 10 mm as criteria for lymph node metastases, the 
results are presented as a ROC-curve in figure 22. Regarding lymph node size ratio, a cut-off 
point of 0.8 resulted in an overall sensitivity and specificity of 85% and 30% respectively 
(Table 7). If the results for size ratio is split by the three anatomical regions, the 
sensitivity/specificity were as follows: region 1, 80/35%; region 2, 54/74% and region 3, 
5/94%, respectively. 
 
                          
Figure 22. Size criteria (≥4, 5, 6, 7, 8 and 10 mm) in shortest diameter according to CT presented as receiver 
operating characteristics (ROC), and area under the curve (AUC). 
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Internal heterogeneity and irregular outer border 
Forty-four out of 119 patients had at least one (range 1-6) lymph node with internal 
heterogeneity according to CT and a total number of 94 lymph nodes with this morphological 
feature were detected. Compared to histopathology, the sensitivity and specificity for 
predicting stage III disease with this criterion was 79 and 84%, respectively, p ≤ 0.001, Odds 
ratio (OR) = 20 (Table 8). If divided by anatomical region, the sensitivity/specificity were as 
follows: region 1, 64/91%; region 2, 51/92% and region 3, 3/97%, respectively. 
Thirty-eight patients had at least one (range 1-8) lymph node with an irregular outer border. 
Compared to histopathology, lymph nodes with an irregular outer border showed sensitivity 
and specificity for prediction of stage III disease of 59 and 81%, respectively, p ≤ 0.001, OR 
= 6.3 (Table 8). If divided by anatomical region, the sensitivity/specificity were as follows: 
region 1, 49/89%; region 2, 33/91%, and region 3, 0/99%, respectively. 
In patients with at least one lymph node with internal heterogeneity and a lymph node with an 
irregular outer border, regardless of location, the sensitivity and specificity for stage III 
disease was 54 and 90%, respectively. Patients with any lymph node showing internal 
heterogeneity and/or irregular outer borders, meaning that either one of the criteria were 
present or both in combination, showed an overall sensitivity and specificity for stage III 
disease of 85 and 75%,respectively, p ≤ 0.001, OR = 16.5 (Table 8). 
Contrast enhancement 
The overall sensitivity and specificity prediction of stage III disease for lymph nodes having a 
HU value ≥50 or ≥100 post contrast in portal venous phase were, 95 and 20%, and 44 and 
68%, respectively (Table 8). 
Cluster of three or more normal shaped and sized lymph nodes 
This criterion resulted in an overall sensitivity of 13% and a specificity of 89% (Table 8). 
        
Table 8. Sensitivity, specificity, PPV and NPV (%) for the different CT characteristics of lymph nodes >4mm in 
shortest diameter compared to histopathology. 
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Combination of different variables using multivariate logistic regression analyses 
The strongest predictor for stage III disease in our study was internal heterogeneity. No other 
variable contributed significantly when the variable internal heterogeneity was included in the 
multivariate regression model (Figure 23). 
 
                   
Figure 23. Multivariate logistic regression analyses for odds ratio of different lymph node characteristics when 
internal heterogeneity is included in the model. 
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4.4 PAPER IV 
“Morphological predictors for lymph node metastases on computed tomography in colon 
cancer.” 
Histopathology 
The majority of the tumours, 56 out of 94 (60%), were right sided located in the caecum and 
ascending colon. The histopathological distribution of T and N stages in the cohort is 
presented in table 1. Thirty-five (37%) of the patients were lymph node positive (Table 9). 
A total of 2086 lymph nodes were harvested (median 20 lymph nodes per patient, range 3-69) 
and of those 173 lymph nodes were assessed as metastases (median 3 lymph nodes per 
patient, range 1-21 (Table 9).  
 
Characteristics  Number (%) 
Sex (female/male)  45/49 
Age (median, range)  72 (45-90) 
 
Histopathological evaluation   
Tumour localization   
Caecum   25 (27%) 
Ascending colon  31 (33%) 
Hepatic flexure   1     (1%) 
Transverse colon  7     (7%) 
Splenic flexure   1     (1%) 
Descending colon  2     (2%) 
Sigmoid colon   27 (29%) 
Tumour Stage   
T1   7     (7%) 
T2   19 (20%) 
T3   58 (62%) 
T4   10 (11%) 
Lymph node status 
N0   59 (63%) 
N1   19 (20%) 
N2   16 (17%) 
Positive lymph node status   
T1 tumours   0/7       (0%) 
T2 tumours   4/19   (21%) 
T3 tumours   25/58 (43%) 
T4 tumours   7/10   (70%) 
Stage   
Stage I   22    (23%) 
Stage II   37    (39%) 
Stage III   35    (37%)    
Lymph nodes, total number   
Harvested lymph nodes PAD  2086 
Positive lymph nodes PAD total  173 
Positive lymph nodes PAD <5mm 56 
Positive lymph nodes PAD 5-10mm 62 
Positive lymph nodes PAD >10mm 18 
 
Table 9. Demographics table of 94 patients/tumours 
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CT evaluation 
T-stage 
In 16 and 21 patients respectively, the observers were not able to detect any tumour (ctT0). 
Twelve (75%) and fourteen (67%), respectively, of those patients had a pT1-T2 tumour 
according to histopathology. Others reached tumour stage pT3a and pT3b. When stratifying 
ctT-stage in not locally advanced (ctT1-T3ab) and locally advanced (ctT3cd-T4) the 
sensitivity and specificity for observer 1 compared to the pT-stage were 79% and 96% , for 
observer 2 61% and 97% and consensus 75% and 97% respectively. Interobserver agreement 
for ctT-stage (Cohens Kappa) was 0.76 (good agreement). 
N-stage 
The assessment of lymph node status (ctN0/N+) was limited to three morphological criteria 
in line with a previous study; a, internal heterogeneity within at least one lymph node (IH) b, 
irregular outer border (IOB) and c, combination of the two criteria, so called combined 
criteria (Figure 24). 
 
a)                                                  b)                                             c) 
Figure 24. CT images of lymph nodes. a) Lymph node without morphological features of malignancy (7x6 mm) 
(white arrow), b) Lymph node (7x6mm) assessed by the criteria IOB (white arrow), c) Lymph node (6x6mm) 
with IH (black/white arrow) and lymph node (7x6mm) with IH and IOB within the same lymph node (white 
arrow).  
The number of lymph nodes and patients with each morphological feature assessed by CT is 
displayed in table 10 as well as sensitivity, specificity, PPV and NPV for each feature.  
Internal heterogeneity 
IH was detected in at least one lymph node in 28 (30%) and 26 (28%) out of 94 patients by 
observer 1 and 2 respectively. A total number of 93 and 64 lymph nodes respectively with 
this morphologic feature were detected for each observer. Sensitivity/specificity for ctN-stage 
compared to pN-stage for both observers were 77/95% and 66/95% respectively. 
Interobserver agreement (Cohens Kappa) for ctN-stage was 0.74 (good agreement). 
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Irregular outer border 
Lymph nodes assessed as presenting IOB were detected at least in one lymph node in 20 and 
19 out of 94 patients respectively by observer 1 and 2. Sensitivity/specificity for ctN-stage 
compared to pN-stage for both observers were 54/97% and 49/97% respectively. 
Both internal heterogeneity and irregular outer border in one lymph node 
The combination of IH and IOB in the same lymph node were assessed in 18 out of 94 
patients by both observers. Sensitivity/specificity for ctN-stage compared to pN-stage for 
both observers were 49/97% and 46/97% respectively. 
Nodal stage – IH, IOB and IH/IOB - combined criteria 
When combining the three possible criteria; IH, IOB or IH/IOB, for lymph nodes and if at 
least one event occurred in one patient, this was assessed in 28 and 27 out of 94 patients 
respectively by both observers. Sensitivity/specificity for ctN-stage compared to pN-stage for 
both observers were 77/95% and 67/95% respectively (Table 10). Interobserver agreement 
(Cohens Kappa) for ctN-stage was 0.72 (good agreement). Consensus ctN-stage compared to 
pN-stage for metastases resulted in a sensitivity and specificity of 69% and 100%. 
 
 IH IOB IH/IOB IH / IOB / (IH/IOB) 
 Obs 1 Obs 2 Obs 1 Obs 2 Obs 1 Obs 2 Obs 1 Obs 2 
No of pat 28 26 20 19 18 18 28 27 
No of ln 93 64 28 24 35 30 93 66 
TN 58 56 57 57 57 57 58 56 
FN 8 12 16 18 18 19 8 11 
FP 1 3 2 2 2 2 1 3 
TP 27 23 19 17 17 16 27 24 
Sensitivity 77 66 54 49 49 46 77 67 
Specificity 95 95 97 97 97 97 95 95 
PPV 96 88 91 90 90 89 96 89 
NPV 88 82 78 76 76 75 88 84 
Table 10. Sensitivity, specificity, positive and negative predictive value for the different CT-criteria for lymph 
node metastases. Note: TN = True negative, FN = False negative, FP = False positive, TP = True positive, 
PPV = Positive Predictive Value, NPV = Negative Predictive Value, IH = Internal Heterogeneity, IOB = 
Irregular Outer Border, IH / IOB / (IH/IOB) = N+ 
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In the present study the major discrepancy was understaging (false negatives, FN) (table 10). 
For observer 1 there were 8 FN cases. In these patients, there were a total of sixteen 
metastatic lymph nodes according to histopathology and none of the metastatic nodes were 
>10 mm in size. Eleven (69%) metastatic lymph nodes were <5 mm. For observer 2 there 
were 11 FN cases with a total of 24 metastatic lymph nodes according to histopathology and 
none of the metastatic nodes >10 mm in size. Fifteen (62%) metastatic lymph nodes were <5 
mm according to histopathology.  
In consensus reading the observers had 11 FN cases according to histopathology. Of the total 
number of 25 lymph node metastases, none were >10 mm, 8 lymph nodes were between 5-10 
mm and 17 (68%) were <5 mm in size. 
 
  55 
5 DISCUSSION AND CONCLUSIONS 
The papers in this thesis has been an attempt to improve detecting colonic lesion in vitro with 
lowering the radiation dose and improve staging colon cancer using CT and MRI. 
In paper I we systematically evaluated CT parameters in a phantom study for detection of 
polyps in the colon. 
This study illustrates the importance of a high axial spatial resolution (i.e., thin slices and low 
pitch) for the detection of polyps in the colon. If no adjustments are done such scanning 
settings result in an increase in the radiation dose to the patient. With adjustment of the tube 
current, polyps can be detected using high-spatial-resolution settings without increasing the 
radiation dose. 
The results of this study indicate that imaging for polyps larger than approximately 5 mm can 
be performed at significantly reduced dose levels without compromising the detection rate. In 
clinical practice polyps smaller than 5 mm are usually of less importance (138, 139). 
CTC involves the definition of objects (polyps) having a high contrast to the surroundings 
(air in the colon). The detection of objects in such high-contrast images is, in general, less 
susceptible to an increased level of stochastic noise and therefore also to a decrease in the 
tube current (and dose) of the CT sequences.  
Other groups have also reported the use of special low-dose protocols in CTC (128, 130, 132, 
140). Although there is evidence that polyps of clinically relevant sizes (5-10 mm) can be 
detected with reduced milliampere-second (mAs) settings in CTC (132), little comparative 
clinical data that prove the relative benefit of using such high-resolution protocols in 
combination with reduced mAs settings is available. 
Because of the obvious differences between artificial phantoms and patients, the three 
observers in study I regarded them as relevant descriptors of the clinical situation. Important 
characteristics of the phantoms in our study that contribute to their relevance in the clinical 
setting are that they were flexible, inflatable, and contained simulated haustral folds. The use 
of artificial removal of residual water and debris has been tested by others but was not used in 
this study nor in the clinical setting at the time (141). 
The presence of water in the phantom increased the detection rate using a 2D MPR 
evaluation, whereas the results of the flythrough technique tended toward the opposite. We 
conclude that misclassification of water drops attached to the wall in the water-filled 
phantoms is always a risk and that such false polyps will influence the detection rate. We do 
not have an obvious explanation of the discrepancies between the results of the two 
evaluation techniques. However, our experience gained from this study indicates that the 
capacity to distinguish different polyp shapes is improved with the fly-through technique 
compared with the 2D MPR technique. This is believed to have influenced the results 
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presented in Figure 8, reducing the number of water drops classified as polyps with the fly-
through compared with the 2D MPR technique. 
At dose levels used in diagnostic X-ray procedures, the associated risk to the patient relates to 
the stochastic induction of cell damage that could cause long-term effects, such as cancer. 
The current belief is that stochastic effects can be induced regardless of the radiation dose, 
with a higher incidence at higher dose levels. The radiation burden to the public from CT 
examinations is significant. A relatively recent study from the United Kingdom showed that 
although CT accounted for only about 4% of all X-ray examinations, it contributed 40% of 
the dose to the population (142). Similar results have been presented by groups in other 
countries (143). The question of screening patients using techniques based on ionizing 
radiation is controversial, and it has not been the intention of this work to cover the topic. If 
the CTC technique could perform significantly better than currently used screening 
techniques in detecting colon cancer and if diagnosis of the disease using screening could 
clearly influence clinical outcome, there might be arguments for introducing CTC as a 
screening for parts of the population. CTC indeed offers a number of advantages over current 
screening techniques for colorectal cancer. 
Today CTC is used both in clinical setting and in screening situations. Modern protocols offer 
different dose options depending on the probability of positive finding.  Modern CT scanners 
have multiple x-ray detectors, today at a minimum of 64. Also the rotation time of the 
generator and detectors are reduced and the combination of table speed enabling full coverage 
of the abdomen during breath hold scans. To overcome the issue of residual content in the 
colon faecal tagging is now often used. The use of computer-aided detection (CAD) has been 
implemented and used as a second reader by some investigators (144, 145). 
In a screening or other clinical settings it is amendable to avoid unnecessary radiation 
exposure and to keep as “As Low As Reasonable Achievable” (ALARA-principle) (146). 
Some patients are difficult to examine with colonoscopy due to long or tortuous colon or 
adhesions after periods of inflammatory events such as diverticulitis. In those patients CTC is 
an alternative. In screening situations, low radiation dose is desirable. The goal is to detect 
polyps >5 mm or tumours and the sensitivity and specificity for CTC in those situations is 
equal to OS. The major limitation with CTC is that there is no possibility to obtain biopsies. 
The major limitation with an increased axial spatial resolution is the prolonged examination 
time, restricting the use of breath-hold techniques depending on the scanner used. The results 
also show that a substantial increase in image noise by the reduced tube current setting can be 
adequate when the analysis is restricted to polyps >5 mm.  
In conclusion, the results of this study indicate that axial spatial resolution plays a dominant 
role for the detection of polyps in the colon using CTC. CTC conducted at a given dose level 
and spatial resolution could therefore possibly perform better at an increased spatial 
resolution (low pitch, thin slices), keeping the dose constant by reducing the tube current 
setting. 
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In paper II we compared high resolution MRI and standard CT for colon cancer staging. 
Both of the modalities can be used to distinguish locally advanced cancers from those that are 
not locally advanced with relatively high accuracy. In a previous systematic review of 
radiological local staging in colon cancer with CT, the weighted accuracy for T-staging was 
67% and for N-staging 69% (87). In this study, we were able to show a higher observed 
agreement (accuracy) by the two observers with MRI 90% (observer 1) and 93% (observer 2) 
than with CT 79% (observer 1) and 76% (observer 2) compared to histopathology in 
categorizing T-stage into locally advanced or not locally advanced. The inter-observer 
agreement (Kappa) between the two observers was also in favour of MRI (0.79) versus CT 
(0.64) for T-stage. Compared to the rectum, the large bowel is a greater challenge for cross-
sectional imaging due to anatomical considerations such as peritoneal coverage, the 
retroperitoneal fascia, bowel motility and tortuosity. One reason for understaging was 
detecting tumour penetrating the serosa, which occurred in 3 out of 4 misclassified tumours 
and one tumour by observer 1 and 2 with MRI, respectively. The corresponding figures for 
CT were 3 out 4 tumours for both observers. 
Regarding nodal staging we demonstrated equal moderate performance between the both 
modalities MRI (accuracy 0.72 and 0.69) and CT (accuracy 0.72 and 0.72) and higher 
sensitivity with MR than with CT, but lower specificity. The accuracies were in line with 
previous CT studies (87, 147). The inter-observer agreement overall was surprisingly low 
with MRI (0.10) but slightly better with CT (0.66). The reason for this was mainly due to 
overstaging of different patients with MRI by the two observers and the criteria for lymph 
node involvement were applied differently by the two observers and/or the criteria were not 
optimal. 
In assessment of EMVI, MRI performed better with accurate staging in 6 out of 8 cases than 
with CT (3 out of 8). MRI showed a higher inter-observer agreement to detect EMVI (k 0.75) 
than CT (k 0.22). In rectal cancer, EMVI has been reported to be identified with a sensitivity 
and specificity of 62% and 88%, respectively (91), but has to our knowledge not been 
evaluated with MRI for colon cancer staging. In colon cancer, Burton et al. showed 
accuracies between 54.5% and 61% in predicting EMVI with CT with poor interobserver 
agreement of 0.178 (82). In our study, the number of patients was too small to draw any firm 
conclusions but it is potentially interesting and worth further studies. 
In this study we identified a number of limitations. A substantial proportion of patients were 
excluded during the study period either due to extensive disease and also periods with limited 
access to MRI scanner. The CT examinations were assessed retrospectively and there were 
variations in scanners configurations and scanning parameters. There were also differences in 
the time between MRI and CT examinations and surgery in different patients which limits the 
conclusions that can be made comparing MRI with CT. There was no matching of individual 
lymph nodes compared to histopathology. Furthermore, diffusion-weighted MR sequences 
(DWI) were not part of the imaging protocol in the study period but would have been 
interesting to apply due to their potential for tumour detection. Regarding stage distribution, 
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only seven patients (25%) in this study proved to have stage III disease, which is rather low 
(148). 
In conclusion, distinguishing locally advanced colon cancer (defined as tumour stage T3cd-
T4) from not locally advanced (T1-T3ab) can be performed with high resolution MRI and 
CT, even when CT is performed with a standard metastasis staging imaging protocol. High 
resolution MRI does have an advantage due to its high soft tissue discrimination to identify 
certain prognostic factors such as T-stage and extramural venous invasion. The down side 
with MRI compared to CT is that the examination often requires a radiologist on site during 
the examination for tumour detection and planning imaging planes and coverage depending 
on tumour localisation the examination. Regarding MRI, the motion artefacts can also be of a 
challenge to work around. 
In paper III we focused on lymph nodes and previously reported criteria for lymph node 
metastases on CT as a predictor for stage III disease in colon cancer. Of all the studied 
imaging criteria in this study, morphological predictors were superior to size and attenuation 
criteria, with reasonable sensitivity and specificity. 
The combination of internal heterogeneity and/or irregular outer borders showed a moderate 
sensitivity of 85% and specificity of 75%. Using logistic regression the strongest predictor for 
stage III disease in our study was internal heterogeneity both alone or combined with other 
variables. Our results, using CT for morphological assessment, are comparable in sensitivity 
but lower in specificity, with a previous work by Brown et al., using morphological predictors 
as mixed signal intensity or irregular border for mesorectal lymph node with MRI of rectal 
cancer with a sensitivity of 85% and specificity of 97% (92). 
Using up to date CT technique, a study with 106 patients using >1 cm and/or cluster of  ≥3 
“normal” lymph nodes as criteria for nodal metastases resulted in a sensitivity of 71% and 
specificity of 41% (149). In our study, only 19 patients had lymph nodes ≥10 mm and only 
14 patients had lymph nodes in a cluster of three, which reduces the impact of these criteria 
for prediction of stage III. Another CT study used size criteria >5 mm and/ or irregular outer 
border were considered to be positive for nodal disease with  sensitivity 64% and specificity 
of 53% (150). If we used this criterion in our study this would have shown a similar 
sensitivity of 56% but a higher specificity of 84%. We have no explanation for this 
difference. 
Our study don not support size criteria alone as predictive for stage III disease. In a previous 
study it has been reported that up to 70% of histopathologically found lymph nodes with 
metastases in colorectal cancer are as small as ≤5 mm in diameter (151). The majority of the 
detected lymph nodes (n = 870, 66%) in our study were <4 mm and thus could not be further 
assessed because of their small size using CT. When using the size threshold of  ≥10 mm of 
the lymph node and a combination of criteria including a cluster of more than three nodes 
along the locoregional vascular pedicle, spiculated and indistinct node borders, and a mottled 
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heterogeneous pattern with CT, Kwak et al. reported sensitivity of 87% and specificity of 
29% (152). The surprisingly low specificity was maybe due to the large threshold. 
Studies using FDG-PET have reported low sensitivities (29–37%) but higher specificity 
(87%) for nodal staging, suggesting that the additional value of PET/CT is limited in 
detecting metastatic regional lymph nodes near the primary tumour area due to high false 
negative rate (153, 154). There are some controversies about the use of PET/CT in primary 
staging in colon cancer. Some authors claim that PET/CT can alter or change the 
management in stage III patients (6.5%) and stage IV patients (12.7%) while other authors 
claim that it does not (155, 156). 
Kanamoto et al. used the criteria of cut-off point of 0.8 or greater in short/long axis diameter 
ratio measured in the axial plane on CT and reported both high sensitivity of 87% and 
specificity of 80%. (136). In study III we measured the true short and long axis and found 
similar sensitivity (85%) for this criterion but much lower specificity (30%) due to a high rate 
of false positive findings (70%). Benign lymph nodes, regardless of size, can be either oval or 
rounded, which is a limitation using this criterion. 
The use of CT for assessment of lymph node status alone as predictor of prognosis is still 
premature at this stage. If the selection for neoadjuvant chemotherapy was based on presence 
of stage III disease using the best combination of criteria (heterogeneity and/or irregular 
border) from study III, 20 patients out of 80 (25%) would be potentially be overtreated and 6 
patients out of 39 (15%) would be undertreated. This emphasizes the need to decide on such 
treatment based on other prognostic factors or use them in combination with the assessed 
lymph node status. 
A strength of study III was that all patients were examined with a 64- multidetector CT and 
all having primary surgery allowing histopathology of the resected specimen as reference.  
The retrospective setting in study III is a limitation. Using only one observer in assessment 
could reduce the evaluation robustness and reproducibility of the imaging criteria. There were 
also some of the criteria that was present in a limited number of patients which limits their 
applicability. There was also no possibility to match individual lymph nodes between 
imaging and histopathology. A possible further limitation was that we excluded T4 tumours 
in the study. The reasons for this was to reduce the possible bias because if relatively high 
rate (37%) of lymph node metastases in this group. At the time of the study, no software 
solution for quantitative analysis for lymph nodes such as texture analysis was available. 
Texture analysis is being evaluated in oncologic CT (157). We believe that texture analysis 
may have a role in the context of characterizing regional lymph nodes on CT in colon cancer 
although the approach is rather unexplored in small lymph nodes and may be subjected to a 
separate study. 
In conclusion, various imaging criteria for lymph node metastases on CT have previously 
been used. Results from study III do not support use of the commonly used size criteria. From 
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study III it can be concluded that imaging criteria that allow the best prediction of nodal 
involvement are either the presence of at least one lymph node with internal heterogeneity or 
the presence of at least one lymph node with internal heterogeneity and/or irregular outer 
border.  
In paper IV the aim of the study was to validate, by two observers, the diagnostic 
performance of morphological lymph node features on CT on a per-patient basis as predictive 
for stage III disease in colon cancer, based on the results in paper III. 
Our results show that that IH and the combined combination assessment of the chosen 
criteria, internal heterogeneity and irregular outer border and a combination of those results in 
a high specificity but moderate sensitivity which are in line with other comparable studies, 
yet inferior to the work using morphological criteria in MRI of rectal cancer (92). The present 
results are better regarding specificity than reports in a recent meta-analysis, including 16 CT 
studies were sensitivity of 71% and specificity of 67% was reported (158). 
Regarding the size of the lymph nodes at histopathology in the pN+ population there were 
only 18 out of 173 (10%) metastatic lymph nodes in 9 out of 35 patients that exceeded 10 
mm. It has been reported in previous studies that nearly 50-70% of the lymph nodes found at 
histopathology are below 5mm in size (151, 159). In our study 56 out of 136 by pathologist 
size measured metastatic lymph nodes (41%) were below 5 mm in size. The large proportion 
of small relative large lymph nodes illustrates the challenge for imaging in assessment of 
metastatic lymph nodes. 
The classification of tumour stage into not locally advanced (T1-T3ab) or locally advanced 
(T3cd-T4) resulted in moderate sensitivity (61-79%) and high specificity (97-97%) in study 
IV. The sensitivity is in line with a recent meta-analysis including four studies with a pooled 
sensitivity of 77% and specificity of 70%, but our study resulted in higher specificity (158). 
Other reports using MRI for detection and staging of colon cancer has shown similar results 
(160-162). In line with study II we understaged the extramural tumour component in T3cd 
tumours and were not able to assess small serosal tumour involvement. 
The selection for neoadjuvant treatment in rectal cancer is based on the clinical stage where 
magnetic resonance imaging plays the most important role. Well-known important prognostic 
factors in colorectal cancer are tumour stage, extramural vascular invasion and lymph node 
involvement (163). Hence, neoadjuvant treatment has resulted in reduction in tumour size and 
recurrence rates (164). 
For colon cancer, there is yet no established neoadjuvant treatment regimen in clinical 
practice. The ongoing FOxTROT trial uses T-stage and extramural tumour depth >5mm as an 
inclusion criteria based on CT. In another study using both CT and MRI for detection of 
lymph node metastases in early colorectal cancer (with submucosal invasion), a sensitivity of 
79% and specificity of 75% was achieved when using size criteria of 4.1 mm in short 
diameter of the lymph node. These authors points out to pay more attention to small nodes in 
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early cancer, because they are more likely to be malignant than reactive as in more advanced 
cancers (165). 
The present study does not support the use of morphological CT criteria alone for prediction 
of stage III disease. The evaluation of the low sensitivity is limited by the limited presence of 
visible morphological features for metastases on CT. The high specificity is caused by false 
negatives and reflects absence of morphological CT criteria in positive lymph node patients 
according to histopathology. The reason for this is that small lymph nodes (<5mm) and 
microscopic tumour growth in normal lymph nodes are not assessable with CT. 
In the scenario of selecting patients for neoadjuvant treatment based on preoperatively 
assessed stage III disease from the morphological criteria in study IV, eleven out of 35 
patients would potentially have been undertreated and none overtreated. On the other hand, if 
a certain neoadjuvant treatment has potential significant side effect to the extent that 
overtreatment is not justified, the high specificity of the morphological criteria on CT may 
play an important role which have to be further investigated. 
The strength of this study is the homogenous consecutive patient cohort. The data was 
prospective collected. All patients were examined with the same CT. The evaluation was 
independent and all patients having primary curative surgery without neoadjuvant treatment 
allowing protocol proforma based detailed histopathology of the resected specimen as a 
reference. This assessment even included not only the number but also size of the lymph 
nodes. 
There are some limitations of the study. The assessment of the morphological imaging 
criteria was performed by two highly experienced radiologists and may not simulate the 
clinical everyday setting. The study was on a per-patient basis and no matching of individual 
lymph nodes between imaging and histopathology was performed. 
The visual assessment was to simulate the clinical setting. No software using quantitative 
analysis of morphology such as texture analysis was used. Texture analysis and other similar 
quantitative tools may potentially have a role in the context of characterizing regional lymph 
nodes on CT in colon cancer although the approaches in this setting are rather unexplored. 
Small size of lymph nodes and presence of microscopic foci of cancer cells within these 
lymph nodes will be challenges when performing such analysis. 
To conclude, morphological criteria for lymph node metastases on CT in colon cancer results 
in high specificity and moderate sensitivity in predicting stage III in colon cancer. 
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Overall conclusion in staging of colon cancer: 
In the routine work up in staging colon cancer patients, CT has relatively high prediction rate 
to classify tumour stage into either not locally advanced or locally advanced. The prediction 
of lymph node metastases with the most commonly used image modalities is unsettled and 
challenged. In the era of selecting patients to neoadjuvant chemotherapy, the ongoing trials 
have used the inclusion criteria based on tumour stage only (T3cd-T4). Patients with lower 
tumour T-stage but presence of regional metastases will therefore potentially be undertreated 
and patients with no metastases will potentially be overtreated. In order to reduce the risk of 
recurrence and prolong survival after curative surgery, other mechanisms may have to be 
taken to account including tumour biology and other prognostic biomarkers at early stage. 
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6 FUTURE ASPECTS 
The detection of colonic lesion using state of the art CT has improved over the years. New 
CT scanners have much larger number of detectors and the standard pixel size is now as thin 
as 0.625 mm or less. The original thin slices from the CT scanner can be reconstructed into 
preferable thickness to overcome to low signal to noise ratio. Modern CT scanners today also 
provide different dose reduction features and the different CT manufacturers use different 
dose reduction techniques. In order to improve the imaging modalities in CRC staging there 
is ongoing continuous work. Regarding CT, the major advantage is the high spatial resolution 
and reproducibility of the technique. In comparison with MRI, there are limitations with CT 
regarding soft tissue discrimination to separate one tissue from another. The DECT technique 
is emerging and may contribute to improve soft tissue contrast resolution on CT (166). 
The use of CTC in colon cancer screening is debated especially in countries with low 
availability for colonoscopy. Several suggestions of low and ultra-low dose protocols have 
now been presented since the time we published study I (167, 168). The use of computer-
aided detection (CAD) in CTC is likely to increase and CTC has been adopted for screening 
in some countries (169). 
In this thesis we used the clinical setting when evaluating the tumour, nodal and metastasis 
stage on CT and MRI with no additional quantitative analysis software tools. Texture analysis 
is one of several upcoming techniques using various different algorithms to quantify the 
image characteristics, even those not clearly visible for the radiological eye. In texture 
analysis, CT images are processed by analysing the pixel value distribution histogram by 
different range of parameters such as entropy, uniformity, kurtosis, skewness and standard 
deviation (157, 170). The technique has been used to differentiate tumours like gastro 
intestinal stroma cells tumour (GIST) into low and high grade, oesophageal cancer and for 
treatment response in breast cancer, characterization of lung nodules, lung cancer and in CTC 
examinations (171). It is a promising technique and prove to have additional value as in 
patients with lung cancer in differentiating between malignant and benign lymph nodes larger 
than 1 cm in the mediastinum (172). It is not yet explored but should be considered to use for 
analysis of lymph nodes in CRC. 
MRI on the other hand has high intrinsic soft tissue discrimination and in specific dedicated 
protocols also high spatial resolution. The evolving hybrid combination of PET/MRI provides 
potential advantage compared to PET/CT allowing for simultaneous assessment of functional 
parameters provided both by PET and MRI. The technique has been used for colorectal 
staging and has proved to have higher accuracy in predicting T-stage and liver metastases 
than PET/CT (173, 174). Although PET/MRI could be used for CRC staging, as well as for 
surgical planning, assessment of treatment response to neoadjuvant therapies and monitoring 
stable and recurrent disease the role is presently unexplored (175). 
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In the era of computer science, artificial intelligence (AI) is growing in many fields of 
development. AI will affect clinical health care and modern imaging of all kinds in the future. 
The AI technique mainly comprises different techniques including machine learning (ML) 
and convolutional neural networks (CNN). The techniques of mathematical algorithms have 
been around for 30 years and have often been designed to precise tasks to discover, classify 
and characterize data. There have been several attempts to implement ML and CNN in 
medicine, both in radiology and histopathology, in evaluating diagnostic imaging with 
encouraging results. AI have been used in mammography, histopathology, automatic 
segmentation of target volume and organ at risk in RT planning in rectal cancer (176-178) 
and has also been used in identification in predictive biomarkers for gene expression (179). 
All this new technology could be of help for radiologist to reduce variability in description 
and quantification and act as clinical decision support. 
The workhorse in today’s functional oncologic imaging, FDG-PET/CT, is associated with 
limitations when dealing with distinction between inflammatory lesions, cancers and 
mucinous tumours. Newer PET agents need to be more tumour specific, such as the targeted 
radiotracers of 68Ga-PSMA for prostate cancers, which is a radionuclide that binds to a 
prostate specific antigen useful to detect tumours and metastases. There are ongoing studies 
concerning a promising PET tracer (124I-CLR1404) which is alkyl phosphocholine (APC) 
analog designed to enter the cancer cells via lipid rafts in the plasma membranes and has been 
proven to be highly selective for malignant tumours and is not retained in inflammatory or 
benign lesions (180). 
Further studies are needed to evaluate the proper criteria in selection patients for neoadjuvant 
treatment. There are several ongoing studies on this matter and they will hopefully soon 
publish their results in a near future (120, 121).  
CRC is a heterogeneous disease. Different tumours have different tumour biology. There are 
small CRC that can metastasize even if the tumour has not penetrated the muscularis mucosae 
(165). The tumour biology may also change over time such as the ability to metastasize and 
the effect from chemotherapy will alter the genetic expression. Great effort is being made in 
searching for predictive biomarkers for predicting the risk of developing metastases, 
recurrence and to assess prognosis. If a representative preoperative biopsy is taken at an early 
stage some prognostic features may alter treatment. Which prognostic factors are the most 
important? Should focus be to further evaluate the varying molecular mechanisms for 
initiating the carcinogenesis? Is it possible to predict the risk of early metastases, prognosis 
and outcome as early as at the stage of the first biopsy? If these questions can be answered, 
the use of diagnostic imaging will change and when performed also focused differently. We 
have to be prepared for this future. 
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